

### **UTILITY PATENT APPLICATION TRANSMITTAL** (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. Army 111A

Total Pages in this Submission

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

**Box Patent Application** Washington, D.C. 20231

Transmitted he invention entitle	erewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent a ed:	pplication for an					
NOVEL "BU	JRST-FREE" SUSTAINED RELEASE POLY-(LACTIDE/GLYCOLIDE) MICROPHE	RES OLA					
and invented b	у:	33.5					
Jeyanthi, et a	al.	je <b>5</b> 49					
If a CONTINU	ATION APPLICATION, check appropriate box and supply the requisite information:						
☑ Continua Which is a:	ation   Divisional   Continuation-in-part (CIP) of prior application No.:	08/590,973					
☐ Continua  Which is a:	ation   Divisional   Continuation-in-part (CIP) of prior application No.:	08/446,149					
☐ Continua	ation Divisional Continuation-in-part (CIP) of prior application No.:						
Enclosed are:	Application Elements						
0 § 1. ⊠ Fili	ing fee as calculated and transmitted as described below						
	ecification having pages and including the following:						
a. 🛚	Descriptive Title of the Invention						
b. 🗵	Cross References to Related Applications (if applicable)						
c. 🗵	c. 🗵 Statement Regarding Federally-sponsored Research/Development (if applicable)						
d. 🗆	d.   Reference to Microfiche Appendix (if applicable)						
e. 🛚	Background of the Invention						
f. 🛚	Brief Summary of the Invention						
g. 🛚	Brief Description of the Drawings (if drawings filed)						
h. 🗵	Detailed Description						
i. 🗵	Claim(s) as Classified Below						
j. 🗵	Abstract of the Disclosure						

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
Army 111

Total Pages in this Submission

	Application Elements (Continued)								
	3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)						
		a.		Formal	Number of Sheets				
		b.	X	Informal	Number of Sheets	8			
	4.		☐ Oath or Declaration						
		a.		Newly executed	original or copy) 🔲 U	Inexecuted			
		b.	X	Copy from a prio	application (37 CFR 1.63(d))	) (for continuation/divisional application only)			
		c.	X	With Power of At	orney 🔲 Without Powe	er of Attorney			
Some Sever Verdi Suell		d.	<ul> <li>DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).</li> </ul>						
and the Anis San Gan A	5.	×	Incorporation By Reference (usable if Box 4b is checked)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
#11 FE	6.		Computer Program in Microfiche (Appendix)						
er med th	7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)						
Same Sur		a.	.   Paper Copy						
Surje Head		b.	.   Computer Readable Copy (identical to computer copy)						
		c.	.   Statement Verifying Identical Paper and Computer Readable Copy						
Accompanying Application Parts									
	8.	×	Assignment Papers (cover sheet & document(s))						
	9.		☐ 37 CFR 3.73(B) Statement (when there is an assignee)						
	10.		English Translation Document (if applicable)						
	11.		Information Disclosure Statement/PTO-1449						
	12.	X	Preliminary Amendment						
	13.	X	Acknowledgment postcard						
	14.	X	Cer	tificate of Mailing					
		☐ First Class ☒ Express Mail (Specify Label No.): EJ696804272US							
			_						

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
Army 111

Total Pages in this Submission

Accompanying Application Parts (Continued)										
15.										
16. [		☐ Additional Enclosures (please identify below):								
										i
Fee Calculation and Transmittal										
	CLAIMS AS FILED									
F	or		#Filed	#Allowed	#Extra		Rate		Fee	
otal Cl	aim	ıs	46	- 20 =	26	x	\$18.00		\$468.00	
idep. Claims 4 - 3			- 3 =	1	x	\$78.00		\$78.00		
ultiple	De	pendent C	laims (check	if applicable)	]				\$0.00	
							E	BASIC FEE	\$760.00	
OTHER	R FE	E (specify	purpose)							
							TOTAL F	ILING FEE	\$1,306.00	
A check in the amount of to cover the filing fee is enclosed.  The Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.  ☐ Charge the amount of \$1,306.00 as filing fee.  ☐ Credit any overpayment.  ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.  ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).										
Reg. No.  Nash & T  3415 Bro  C: Brookevi					Caroline M. Nash Reg. No. 36, 329  Nash & Titus, LLD  3415 Brookeville Rd., Suite 1000  Brookeville, Maryland 20833					

CERTIFICATE OF I	Docket No.  Army 111A							
Serial No. Cont. of 08/590,973	Filing Date June 22, 1999	Examiner Harrison, R.	Group Art Unit 1617					
Invention: NOVEL "BURST-FREE" SUSTAINED RELEASE POLY-(LACTIDE/GLYCOLIDE) MICROSPHERES								
I hereby certify that this Assignment Recordation Form Cover Sheet, Transmittal Letter and Assignments (7)  (Identify type of correspondence)  is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.								
37 CFR 1.10 in an er 20231-0001 on	June 22, 1999 (Date)	Caroline (Typed or Printed Name of Person  (Signature of Person Mailin  EJ6968042 ("Express Mail" Mailing	Nash Mailing Ma ng Corre	r Correspondence)  Spondence)				
Note: Each paper must have its own certificate of mailing.								

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of JEYANTHI et al.
Rule 53(b) Continuation appl. Of Appln. No.: 08/590,973

Filed: January 24, 1996

Group Art Unit: 1617

Examiner: Harrison, R.H.

FOR: NOVEL "BURST-FREE" SUSTAINED RELEASE POLY-(LACTIDE/GLYCOLIDE) MICROSPHERES

\* \* \* \* \*

June 22, 1999

### PRELIMINARY AMENDMENT

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In connection with the above-referenced continuation application filed concurrently herewith, please enter the following amendments before examination on the merits.

### **IN THE SPECIFICATION:**

Page 1, line 14, after "is" insert --- a continuation application of U.S. Patent Application Serial No. 08/590,973, filed January 24, 1996, which is --.

Page 6, line 20, delete "12k" second occurrence.

Page 8, line 19, replace "coploymer" with -copolymer--.

Page 12, line 16, after "13" insert —wherein the biologically active agent is a polypeptide--;

line 23, delete "of" first occurrence;

line 25, replace "microshreres" with --microspheres--.

```
Page 18, line 3, replace "precipitous" with -precipitous--;
         line 7, replace "yor" with -or--;
         line 13, after "other' insert -biologically active agents from--.
Page 27, line 5, replace "microshperes" with -microspheres--;
         line 22, after "1-12", replace "weeek" with -week--.
Page 28, line 14, replace "actice" with -active--;
         line 20, replace "rations" with -ratios--;
         line 50, replace "1a and 1b" with --2 and 4--.
Page 29, line 32, replace "2" with --5--;
         line 49, replace "2" with --5--.
Page 30, line 13, replace "3" with--5--;
         line 28, replace "2" with --3--;
         line 43, replace "3" with ---5--.
Page 31, line 6, replace "3" with ---5--;
         line 22, replace "2" with ---3--;
          line 33, replace "is" with -are--;
          line 34, replace "; and is" with --. They are--;
          line 35, replace "4" with ---7--.
Page 32, line 20, replace "2 and 3" with --3 and 5--;
```

line 24, replace "these figures" with -- Figure 6--.

### **IN THE CLAIMS:**

Please amend the claims as follows:

- 1. (Amended) A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a biologically active agent over a duration from 1-100 days, comprising an active agent and [a blend of] uncapped and end-capped biodegradable poly(lactide/glycolide) polymers.
- 2. (Amended) The microcapsule pharmaceutical formulation of claim 1, wherein [the biodegradable poly (lactide/glycolide) is a blend of] a copolymer ratio of uncapped and end-capped forms of biodegradable poly (lactide/glycolide) polymers [capped forms, in ratios ranging from] is 100/0 to 1/99.
- 3. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2] claim 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and [endcapped] end-capped polymer is 52/48 to 48/52.
- 4. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2] claim 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and end-capped polymer is 90/10 to 40/60.
- 5. (Amended) The [microcapsules] <u>microcapsule pharmaceutical formulation</u> of claim 3 wherein the molecular weight of the copolymer is between 2,000-60,000 daltons.
- 6. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 1 wherein the biologically active agent is a peptide or polypeptide.

- 7. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6, wherein said polypeptide is histatin [consisting of 12 amino acids and having a molecular weight of 1563].
- 8. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to completely release the histatin in an aqueous physiological environment from 1-35 days with a 100/0 [blend] ratio of uncapped and end-capped poly(lactide/glycolide) having an L/G ratio of 48/52 to 52/48, and a molecular weight <15,000 daltons.
- 9. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to completely release the histatin in an aqueous physiological environment from 18-40 days with a 100/0 [blend] ratio of uncapped and end-capped poly(lactide/glycolide) having an L/G ratio of 48/52 to 52/48 and a molecular weight range of 28,000-40,000 daltons.
- 10. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to release up to 90% of the histatin in an aqueous physiological environment from 28-70 days with a 0/100 [blend] ratio of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 10,000 40,000 daltons.
- 11. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to release up to 80% of the histatin in an aqueous physiological environment from 56-100 days with a 0/100 [blend] ratio of

uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 75/25 and a molecular weight of <15,000 daltons.

- 12. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 7 or 8 or 9 or 10 or 11] claim 7 having analogs of histatin with chain lengths of from 11-24 amino acids of molecular weights from 1,500-3,000 daltons and characterized by the following structures:
  - 1. DSHAKRHHGYKRKFHEKHHSHRGY
  - 2. KRHHGYKRKFHEKHHSHRGYR
  - 3. KRHHGYKRKFHEKHHSHR
  - 4. RKFHEKHHSHRGYR
  - 5. AKRHHGYKRKFH
  - 6. \*AKRHHGYKRKFH
  - 7. KRHHGYKRKF

13. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 wherein the biologically active agent is a polypeptide Leutinizing hormone releasing hormone (LHRH) that is decapeptide of molecular weight 1182 in its acetate form, and having the structure:

### p-EHWSYGLRPG.

14. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 comprising a polypeptide, wherein said polypeptide has [having] a molecular weight of from 1,000 to 250,000 daltons.

<sup>\*</sup>d-amino acid.

- 15. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14] claim 1 wherein [release profiles of variable] varying release rates and varying release durations of the active agent are achieved by blending uncapped and [capped microspheres] end-capped polymers as a cocktail in variable amounts.
- 16. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14] claim 1 wherein [release of profiles of variable] varying release rates and varying release [duration] durations are achieved by varying a ratio of [blending] uncapped and [capped polymer] end-capped polymers [in different ratios] within the same [microshreres] microcapsules.
- 17. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 [or 7 or 8 or 9 or 10 or 11 or 13 or 14] wherein the [entrapped] active agent is a polypeptide and said polypeptide is [any of the] a vaccine [agents] agent against enterotoxigenic E. coli (ETEC) [such as CFA/I, CFA/II, CS1,CS3, CS6 and CS17 and other ETEC-related enterotoxins].
- 18. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 [or 7 or 8 or 9 or 10 or 11 or 13 or 14] wherein the [entrapped] active agent is a polypeptide and said polypeptide [consists of] comprises peptide antigens for immunization against enterotoxigenic E. coli (ETEC) [of] having a molecular weight range of about 800-5000 daltons [for immunization against enterotoxigenic E. coli (ETEC)].

- 19. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5] claim 1, wherein said biologically active [agents are] agent is selected from the group consisting of water-soluble hormone drugs, antibiotics, antitumor agents, anti inflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, and antinarcotics, in the molecular weight range of 100-100,000 daltons.
- 20. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8] claim 1, wherein said biodegradable poly(lactide/glycolide) is in an oil phase, and is present in about 1-50% (w/w).
- 21. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14] claim 1, wherein a concentration of the active agent is in [the] a range of 0.1 to about 60% (w/w).
- 22. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14] claim 1, wherein a ratio of [the] an inner aqueous to oil [phases] phase is about 1/4 to 1/40 (v/v).

Claim 25, line 1, replace "claims 23 or 24" with --- claim 23---.

Claim 26, line 1, replace "claims 23 or 24" with --- claim 23---.

28. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6, wherein, when the [entrapped] said active agent is a polypeptide and said polypeptide is active at a low pH and is entrapped in said polymers, [such as LHRH, adrenocorticortropic hormone, epidermal growth factor, calcitonin released] said polypeptide is bioactive when released.

29. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11] claim 6, wherein[,] said active agent is a peptide and when [entrapped] the peptide [such as histatin] is entrapped and is inactive at a low pH, a pH-stabilizing agent of inorganic salts [are] is added to [the] an inner aqueous phase during manufacture of said microcapsule to maintain biological activity of the released peptide.

30. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11] claim 6, wherein, when [entrapped] said active agent is a polypeptide, the polypeptide [such as histatin] is inactive at a low pH, a non-ionic surfactant [such as] selected from the group consisting of polyoxyethylene sorbitan fatty acid esters (Yween 80, Tween 60, and Tween 20) and polyoxyethylene — polyoxypropylene block copolymers (Pluronics) is added to [the] an inner aqueous phase during manufacture to maintain biological activity of the released polypeptide.

31. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 29, wherein placebo [spheres] microcapsules loaded with the pH-stabilizing agents are coadministered with the polypeptide-loaded [spheres] microcapsules to maintain [the] a solution pH around the polypeptide-loaded microcapsules and preserve [the] biological

activity of [the] released <u>peptides</u> [peptide in instances where the addition of pH-stabilizing agents in the inner aqueous phase is undesirable for the successful encapsulation of the acid pH sensitive polypeptide].

- 32. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 29, wherein placebo [spheres] microcapsules loaded with non-ionic surfactant are coadministered with polypeptide-loaded microcapsules [spheres] to maintain biological activity of released peptides [peptide where the addition of non-ionic surfactants in the inner aqueous phase is undesirable for successful encapsulation of the acid pH sensitive polypeptide].
- 33. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14] claim 2, wherein [comprising a blend of] said uncapped and [capped] end-capped polymers [polymer, wherein] are present in an amount wherein complete solubilization of the copolymer leaves no residual [polymer] polymers at [the] a site of administration and occurs concurrently with [the] a complete release of the [entrapped] active agent from said microcapsule.
- 34. A process for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering parenterally to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via parenteral routes, such as intramuscular and subcutaneous].

- 35. (Amended) A process for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering topically to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via topical routes].
- 36. (Amended) A process for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering orally to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via oral routes].
- 37. (Amended) A process <u>for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering nasally, rectally, transdermally or vaginally to said animal a pharmaceutically-effective amount of a microcapsule of claim

  1 [of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or

  13 or 14 for human administration via nasal, transdermal, rectal, and vaginal routes].</u>

Please add the following claims:

--38. (New) The microcapsule pharmaceutical formulation of claim 17, wherein said enterotoxigenic E. coli is selected from the group consisting of CFA/I, CFA/II, CS1,CS3, CS6 and CS17 and other ETEC-related enterotoxins.

- 39. (New) The microcapsule pharmaceutical formulation of claim 28, wherein said polypeptide is selected from the group consisting of LHRH, adrenocorticortropic hormone, epidermal growth factor and calcitonin.
- 40. (New) The process of claim 34, wherein said administering parenterally comprises administering intramuscularly or subcutaneously.
- 41. (New) A process of maintaining a solution pH around the polypeptide-loaded microcapsule of claim 6, comprising coadministering placebo microcapsules loaded with pH-stabilizing agents with the polypeptide-loaded microcapsules, wherein said placebo microcapsules preserve biological activity of peptides released from said polypeptide loaded microcapsules.
- 42. (New) A process of maintaining biological activity of released peptide comprising coadministering placebo microcapsules loaded with non-ionic surfactant with said microcapsule pharmaceutical formulation of claim 29.
- 43. (New) The microcapsule pharmaceutical formulation of claim 7, wherein said histatin consists of 12 amino acids and has a molecular weight of 1563.
- 44. (New) A controlled release microcapsule pharmaceutical formulation for burst-free sustained, programmable release of biologically active agent over a duration from 1-100 days, comprising an active agent encapsulated within a biodegradable poly(lactide/glycolide) having a lactide/glycolide ratio of 90/10 to 40/60 and the end capped/uncapped form of said poly(lactide/glycolide) in the ratio of 100/0 to 1/99.
- 45. (New) The process of claim 24, wherein a solvent-saturated external aqueous phase is added to emulsify the inner w/o emulsion prior to addition of the external

aqueous layer, to provide microcapsules of narrow size distribution range between 0.05-500µm.

46. (New) The process of claim 24, wherein a low temperature of about 0-4°C is provided during preparation of the inner w/o emulsion, and a low temperature of about 4-20°C is sprovided during preparation of the w/o/w emulsion to provide a stable emulsion and high encapsulation efficiency.--.

### **REMARKS**

An early and favorable action on the merits is respectfully requested.

Claims 1-46 are pending in the application. Claims 1-22, 25, 26 and 28-37 have been amended. Claims 38-46 are newly added. The specification has also been amended to correct various spelling, grammatical and idiomatic errors. No new matter has been added.

The claims have been amended to specifically address the Examiner's comments and section 112 rejections in the office actions of the parent application 08/590,973.

Additionally, the terms "uncapped" and "end-capped" are defined in the specification at page 8, lines 5-18.

The Examiner indicated in the parent application (08/590,973) that claim 38 was allowable. Claim 38 of the parent application (08/590,973) appears in this Preliminary Amendment as new claim 44. Hence, it is believed that new claim 44 would also be allowable.

If the Examiner has any questions, or would like to suggest alternative claim language, he is invited to contact Applicant's representative at (301) 924-9500.

Respectfully submitted,

By

Caroline Nash, Reg. No. 36, 329

for: Charles H. Harris, Reg. No. 34,616

Attorney for Applicants
U.S. Army Medical Research
and Materiel Command

ATTN: MCMR-JA

Fort Detrick, MD 21702-5012

## NOVEL, "BURST-FREE" SUSTAINED RELEASE POLY(LACTIDE/GLYCOLIDE) MICROSPHERES

5

### I. GOVERNMENT INTERESTS

The invention described herein may be manufactured, licensed and used by or for governmental purposes without the payment of any royalties to us thereon.

### II. CROSS REFERENCE

This application is a continuation-in-part of U.S. Patent application Serial No. 08/446,149, filed May 22, 1995.

### III. FIELD OF THE INVENTION

20

This invention relates to providing novel biocompatible and biodegradable microspheres for burst-free programmable sustained release of biologically active agents, inclusive of polypeptides, over a period of up to 100 days in an aqueous physiological environment.

25

25

5

### IV. BACKGROUND OF THE INVENTION

Several publications and patents are available for sustained release of active agents from biodegradable polymers, particularly, poly(lactide/glycolides) (PLGA). Prior usages of PLGA for controlled release of polypeptides have involved the use of molar ratios of lactide/glycolide (L/G) of 75/25 to 100/0 for molecular weights >20,000. Further prior art preparations of PLGA utilized fillers or additives in the inner aqueous layer to improve the stability and encapsulation efficency and/or to increase the viscosity of the aqueous layer, thereby modulating polymer hydrolysis and the biologically active agent or polypeptide release.

In addition, the prior art use of PLGA copolymers were end-capped, in that the terminal carboxyl end groups were blocked. In these end-capped co-polymers, the microcapsule preparations exhibited a low to moderate burst release of ~ 10-40% of the entrapped polypeptide in the first 24 hours after placement in an aqueous physiological environment. In part, these characteristics are due to the use of fillers in the inner aqueous phase.

Further, a 1-month release of polypeptide is known with the use of a 75/25 co-polymer of PLGA of Mw <20,000.

Investigations in controlled release research has been proceeding especially to obtain a 1 to 2 month delivery system

for biologically active agents or polypeptides using poly(lactide/glycolide) polymers. However, most of these systems have one or more of the following problems: Poor encapsulation efficency and large 'burst release' followed by an intermediate 'no release' or 'lag phase' until the polymer degrades. In general, release from these polymers occur over a period from about 4 weeks to about several months. In addition, in order to achieve this release a 50/50 copolymer of MW > 30,000 or a 75/25 copolymer of Mw > 10,000 are employed which often results in residual polymer remaining at the site of administration long after the release of active core.

### V. SUMMARY OF THE INVENTION

This invention provides biocompatible and biodegradable microspheres that have been designed for novel, burst free, programmable sustained release of biologically active agents, including polypeptides over a period of up to 100 days in an aqueous physiological environment.

Unlike currently available release systems, which rely on the use of fillers/additives such as gelatin, albumin, dextran, pectin, polyvinyl pyrrolidone, polyethylene glycol, sugars, etc., and are still prone to low encapsulation efficiencies and "burst effects", this invention achieves high encapsulation and "burst-free" release without the use of any additive. In this invention, burst-free, programmable sustained release is achieved through the use of a unique blend of the 'uncapped' and end-capped forms of poly(lactide/glycolide) polymer in the molecular weight range of 2,000 to 60,000 daltons.

20

25

In general, microspheres described in this invention are produced by a unique emulsification technique wherein an inner water-in-oil (w/o) emulsion is stabilized by dispersing in a solvent-saturated aqueous phase containing an emulsion stabilizer. A ternary w/o/w emulsion is then formed by emulsifying the above w/o emulsions in an external pre-cooled aqueous phase containing an o/w emulsifier. Essentially, the

25

5

inner w/o emulsion is comprised of an aqueous layer containing from ~ 2 to about 20% (w/w) of the active agent to be entrapped and an oil layer containing poly(lactide/glycolide) copolymer in concentrations ranging from ~ 5 to about-- 50% (w/w oil phase). The copolymer includes molecular weight ranging from 2,000 to about 60,000 daltons, with molar composition of lactide/glycolide from 90/10 to 40/60 and a blend of its uncapped and end-capped forms in a ratio of 100/0 to 1/99. Very high encapsulation efficiencies of about 80 to 100% are achieved depending on polymer molecular weight and structural form.

Programmable release of active core over variable durations between 1-100 days is achieved by a judicious selection of process parameters such as polymer concentration, peptide concentration and the aqueous/oil phase ratio.

This invention is particularly suitable for high encapsulation efficiencies and burst-free, continuous programmable release of polypeptides of molecular weights ranging from 1,000 to about 250,000 daltons, and also other biologically active agents over a period of 1-100 days. A uniqueness of the invention is that when using a 100/0 blend of the uncapped and capped polymer, the final phase of active core release is concurrent with the complete solubilization of the polymer to innocuous components, such as lactic and glycolic acids. This is a significant advantage over the currently available 30 day - release systems wherein a major regulatory concern is about toxicity of residual polymer at the site of administration, long

25

5

after release of the active core.

The microcapsules described in this invention are suitable for administration via several routes such as parenteral (intramuscular, subcutaneous), oral, topical, nasal, rectal and vaginal routes.

### VI. BRIEF DESCRIPTION OF DRAWINGS

- FIG. 1 shows a comparison of drug release from a conventional system versus a controlled release system. Peak and valley levels from conventional administrations are shown, in contrast to the steady therapeutic levels from the controlled release administration.
- FIG. 2 shows a scanning electron micrograph of PLGA microspheres prepared by the process described in the invention using 50/50 uncapped polymer of Mw 8-12k dalton and shows superior sphere morphology, sphere integrity, and narrow size distribution.
- FIG. 2a shows a scanning electron micrograph of PLGA microspheres prepared by conventional solvent evaporation method using a 50/50 12k uncapped polymer of Mw 8-12k dalton.
- FIG. 3 shows cumulative Histatin release from PLGA microspheres, wherein release profiles from several batches are prepared using 50/50, uncapped polymer (of Mw 8-12k dalton) and wherein the process parameters are varied to modulate release between 1 and 35 days.
  - FIG. 4 shows a scanning electron micrograph of solid, smooth

25

5

spherical surfaces of PLGA microspheres prepared by the method of in the invention using 50/50, end-capped polymer (of Mw 30-40k dalton).

FIG. 5 shows cumulative Histatin release from PLGA microspheres, wherein the release profiles are from several batches prepared using 50/50, uncapped and end-capped polymer of Mw 30-40k daltons, and wherein the process parameters are varied to modulate release between 28 to 60 days.

FIG. 6 shows cumulative Histatin release from PLGA microspheres, wherein combined release profiles from several batches have been prepared using 50/50, uncapped and end-capped polymer of Mw 8-40k daltons, while varying the process parameters to modulate release between 1 and 60 days.

FIG. 7 shows a cumulative percent release of LHRH from PLGA microspheres prepared using uncapped polymer of Mw 8-12 daltons.

### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to the design of biocompatible and biodegradable microspheres for novel, programmable sustained release of biologically active agents, including polypeptides over a period of up to 100 days in an aqueous physiological environment with little or no burst release.

Unlike currently available release systems which rely on the use of fillers/additives such as gelatin, albumin, dextran, pectin, polyvinyl pyrrolidone, polyethylene glycol, sugars, etc., and are still prone to low encapsulation efficiencies and "burst effects", this invention achieves high encapsulation efficiency

25

5

and 'burst-free' release without the use of any additive. In this invention, burst-free, programmable sustained release is achieved through the use of a unique blend of the 'uncapped' and end-capped forms of poly (lactide/glycolide) polymer.

The 'uncapped' form refers to "poly(lactide/glycolide) with free carboxyl end groups" which renders the polymer more . hydrophilic compared to the routinely used end-capped form. Currently used 'end-capped' polymer hydrates between 4-12 weeks depending on the molecular weight, resulting in an intermediate 'no release' or a 'lag phase'. The uncapped polymer hydrates typically between 5 to 60 days depending on the molecular weight, thus releasing its core continuously without a lag phase. A careful blend of the two forms and appropriate molecular weights and L/G ratios, results in a continuous release between 1 to 100 days. In addition, release within this time is programmable by a judicious selection of process parameters such as polymer concentration, peptide concentration and the aqueous/oil phase ratio.

The coploymer in this invention includes molecular weight ranging from 2,000 to 60,000 daltons, a lactide/glycolide ratio of 90/10 to 40/60 and a blend of the uncapped/capped forms in the ratio of 100/0 to 1/99. The molecular weight of the polypeptide may be in the range of 1000 to 250,000 daltons while that of other biologically active agents may range from 100 to 100,000 daltons.

Microcapsules described in this invention are prepared by a

unique aqueous emulsification techinique which has been developed for use with the uncapped polymer to provide superior sphere morphology, sphere integrity and narrow size distribution. This is accomplished by first preparing an inner water-in-oil (w/o) by mixing the solutions of polymer in an organic solvent such as methylene chloride and the biologically active agent in water. This is followed by stabilization of the w/o emulsion in a solvent-saturated aqueous solution containing an o/w emulsifier such as polyvinyl alcohol. A ternary emulsion is then formed by emulsifying the w/o emulsion in an external aqueous phase containing the same emulsifier as above at concentrations ranging from 0.25 - 1% w/v. Microcapsules are hardened upon solvent removal by evaporation, rinsed to remove residual emulsifier and lyophilized. Low temperature is used both at the time of primary emulsification (w/o emulsion formation) and during the formation of the final w/o/w emulsion to achieve stable emulsion and superior sphere characteristics.

In the context of the invention, a biologically active agent is any water-soluble hormone drugs, antibiotics, antitumor agents, antiinflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, antinarcotics, etc.

20

25

5

More precisely, applicants have discovered a pharmaceutical composition and process with the following itemized features:

- 1. A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a biologically active agent over a duration from 1-100 days, comprising an active agent and a blend of uncapped and end-capped biodegradable poly(lactide/glycolide).
- 2. The pharmaceutical formulation of item 1, wherein the biodegradable poly(lactide/glycolide) is a blend of uncapped and capped forms, in ratios ranging from 100/0 to 1/99.
- 3. The microcapsules of items 1 or 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and endcapped polymer is 52/48 to 48/52.
- 4. The microcapsules of items 1 or 2 wherein the copolymer L/G ratio for uncapped and end-capped polymer is 90/10 to 40/60.
- 5. The microcapsules of items 1 or 2 or 3 or 4 wherein the molecular weight of the copolymer is between 2,000-60,000 daltons.
- 6. The microcapsules of items 1 or 2 or 3 or 4 or 5 wherein the biologically active agent is a peptide or polypeptide.
- 7. The microcapsules of item 6, wherein said polypeptide is histatin consisting of 12 amino acids and having a molecular weight of 1563.
- 8. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to completely release histatin in

25

5

an aqueous physiological environment from 1-35 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48, and a molecular weight <15,000.

- 9. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to completely release histatin in an aqueous physiological environment from 18-40 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 28,000-40,000.
- 10. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to release up to 90% of the histatin in an aqueous physiological environment from 28-70 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 10,000-40,000 daltons.
- 11. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to release up to 80% of histatin in an aqueous physiological environment from 56-100 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 75/25 and a molecular weight of < 15,000 daltons.
- 12. The microcapsules of items 7 or 8 or 9 or 10 or 11 having analogs of histatin with chain lengths of from 11-24 amino acids of molecular weights from 1,500-3,000 daltons and characterized by the following structures:
  - 1. D S H A K R H H G Y K R K F H E K H H S H R G Y

25

5

- 2. KRHHGYKRKFHEKHHSHRGYR
- 3. KRHHGYKRKFHEKHHSHR
- 4. RKFHEKHHSHRGYR
- 5. AKRHHGYKRKFH
- 6. \*AKRHHGYKRKFH
- 7. KRHHGYKRKF
- \* D-amino acid
- 13. The microcapsules of items 1 or 2 or 3 or 4 or 5 wherein the biologically active agent is a polypeptide Leutinizing hormone releasing hormone (LHRH) that is a decapeptide of molecular weight 1182 in its acetate form, and having the structure:

### p- E H W S Y G L R P G

- 14. The microcapsule of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 having a molecular weight of from 1,000 to 250,000 daltons.
- 15. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 wherein release profiles of variable rates and durations are achieved by blending uncapped and capped microspheres as a cocktail in variable amounts.
- 16. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 wherein release of profiles of variable rates and duration are achieved by blending uncapped and capped polymer in different ratios within the same microshreres.
  - 17. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11

25

5

or 12 or 13 or 14 or 15 or 16 wherein the entrapped polypeptide is any of the vaccine agents against enterotoxigenic E. coli (ETEC) such as CFA/I,CFA/II,CS1,CS3,CS6 and CS17 and other ETEC-related enterotoxins.

- 18. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 wherein the entrapped.

  polypeptide consists of peptide antigens of molecular weight range of about 800-5000 daltons for immunization against enterotoxigenic E. coli (ETEC).
- 19. The microcapsules of items 1 or 2 or 3 or 4 or 5 wherein said biologically active agents are selected from the group consisting of water-soluble hormone drugs, antibiotics, antitumor agents, anti inflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, and antinarcotics, in the molecular weight range of 100-100,000 daltons.
- 20. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 wherein said biodegradable poly(lactide/glycolide) is in an oil phase, and is present in about 1-50% (w/w).
- 21. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 wherein concentration of the active agent is in the range of 0.1 to about 60% (w/w).
  - 22. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or

25

5

8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 wherein a ratio of the inner aqueous to oil phases is about 1/4 to 1/40(v/v).

- 23. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising: Dissolving biodegradable poly (lactide/glycolide), in uncapped form in methylene chloride, and dissolving a biologically active agent or active core in water; adding the aqueous layer to the polymer solution and emulsifying to provide an inner water-in-oil (w/o) emulsion; stabilizing the w/o emulsion in a solvent-saturated aqueous phase containing a oil-in-water (o/w) emulsifier; adding said w/o emulsion to an external aqueous layer containing oil-in-water emulsifier to form a ternary emulsion; and stirring the resulting water-in-oil-in-water (w/o/w) emulsion for sufficient time to remove said solvent, and rinsing hardened microcapsules with water and lyophilizing said hardened microcapsules.
- 24. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising:

dissolving biodegradable poly(lactide/glycolide) in endcapped form in methylene chloride, and dissolving a biologically active agent or active core in water; adding the aqueous layer to the polymer solution and emulsifying to provide an inner waterin-oil emulsion; stabilizing the w/o emulsion in a solventsaturated aqueous phase containing a oil-in-water (o/w)

25

5

emulsifier; adding said w/o emulsion to an external aqueous layer containing oil-in-water emulsifier to form a ternary emulsion; and stirring a resulting water-in-oil-water (w/o/w) emulsion for sufficient time to remove said solvent; and rinsing hardened microcapsules with water; and lyophilizing said hardened microcapsules.

- 25. The process of items 23 or 24 wherein a solvent-saturated external aqueous phase is added to emulsify the inner w/o emulsion prior to addition of the external aqueous layer, to provide microcapsules of narrow size distribution range between  $0.05-500\mu m$ .
- 26. The process of items 23 or 24, wherein a low temperature of about 0-4°C is provided during preparation of the inner w/o emulsion, and a low temperature of about 4-20°C is provided during preparation of the w/o/w emulsion to provide a stable emulsion and high encapsulation efficiency.
- 27. The process of items wherein a 100/0 blend of uncapped and end-capped polymer is used to provide release of the active core in a continous and sustained manner without a lag phase.
- 28. The microcapsules of items 6, wherein, when the entrapped polypeptide is active at a low pH, such as LHRH, adrenocorticotropic hormone, epidermal growth factor, calcitonin released polypeptide is bioactive.
- 29. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11, wherein, when entrapped peptide such as histatin is inactive at a low pH, a pH-stabilizing agent of inorganic salts are added to

25

5

the inner aqueous phase to maintain biological activity of the released peptide.

- 30. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 wherein, when entrapped polypeptide such as histatin is inactive at a low pH, a non-ionic surfactant such as polyoxyethylene sorbitan fatty acid esters (Tween 80, Tween 60 and Tween 20) and polyoxyethylene polyoxypropylene block copolymers (Pluronics) is added to the inner aqueous phase to maintain biological activity of the released polypeptide.
- 31. The microcapsules of items 29, wherein placebo spheres loaded with the pH-stabilizing agents are coadministered with polypeptide-loaded spheres to maintain the solution pH around the microcapsules and preserve the biological activity of the released peptide in instances where the addition of pH-stabilizing agents in the inner aqueous phase is undesirable for the successful encapsulation of the acid pH sensitive polypeptide.
- 32. The microcapsules of item 30 wherein placebo spheres loaded with non-ionic surfactant are coadministered with polypeptide-loaded spheres to maintain biological activity of the released peptide where the addition of non-ionic surfactants in the inner aqueous phase is undesirable for successful encapsulation of the acid pH sensitive polypeptide.
- 33. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 comprising a blend of uncapped and capped polymer, wherein complete

solubilization of the copolymer leaves no residual polymer at the site of administration and occurs concurrently with the complete release of the entrapped agent.

- 34. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via parenteral routes, such as intramuscular and subcutaneous.
- 35. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via topical route.
- 36. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via oral routes.
- 37. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via nasal, transdermal, rectal, and vaginal routes.

25

20

25

5

### Conservation of bioactivity of polypeptides

As the polymer degrades rapidly, there is a preciptitous drop in pH accompanied by the release of soluble oligomers in the microenvironment which may affect the biological activity of acid pH-sensitive peptides/proteins. In such instances, biological activity can be maintained by the use of inorganic salts yor buffering agents in the inner aqueous phase codissolved with the peptide.

The following unique advantages are characteristics of this invention:

- 1. Burst-free, prolonged, sustained release of polypeptides and other biocompatible and biodegradable microcapsules up to 100 days in an aqueous physiological environment without the use of additives in the core.
- 2. Release of active core programmable for variable durations over 1-100 days, by using a blend of uncapped and capped polymer of different molecular weights and copolymer ratio, and by manipulating the process parameters.
- 3. Complete release of the active core is concurrent with complete solubilization of the carrier polymer to innocuous components, such as lactic and glycolic acids, especially when using a 100/0 blend of uncapped/capped polymer. This is of tremendous significance, as most biodegradable polymers currently used for 1-30 day delivery, do not degrade completely at the end of the intended release duration, thereby causing serious concern

25


5

of regulatory authorities on the effects of residual polymer at the site of administration.

4. Ease of administration of the microcapsules in various dosage forms via several routes, such as parenteral (intramuscular and sucutaneous), oral, topical, nasal, vaginal, etc.

The hydrophilic homo-and co-polymers based on D,L-lactide and glycolide contains hydrophilic adjusted homo-and co-polymers with free carboxylic end groups, and is characterized by the formula:

Poly(D,L-lactide-co-glycolide) 50:50



 $(c_3H_4o_2)_n(c_2H_2o_2)_m$ 

n:m = 1:1

Wherein Z= Molecular Weight/130; for example Z=92 for Mw 12,000 and 262 for Mw 34,000.

While the molar ratio of the lactide to glycolide may vary, it is most preferred that the lactide to glycolide copolymer ratio be 50:50.

Reference is now made to FIG. 1 which depicts a blood-drug concentration versus time graph that shows conventional drug administration using a series of dosages compared to an ideal controlled release system. Unfortunately, many drugs have a

25

5

therapeutic range, above which they are toxic and below which they are ineffective. Oscillating drug levels that are commonly observed following systemic administration causes alternating periods of ineffectiveness and toxicity. A sustained-release encapsulated biologically active agent or polypeptide preparation, ideally, will maintain the drug in the desired therapeutic range by means of a single dose, as depicted in the THERAPEUTIC RANGE in FIG.1, where the ideal case for controlled release is shown.

In FIG. 2, there is shown a scanning electron micrograph of PLGA microspheres prepared using 50/50 uncapped polymer of Mw 8-12k dalton. The uncapped polymer has solid, smooth spherical surfaces, and is suited to provide a "burst free" release system.

Table I is a summarization of the microsphere process description for preparing a peptide system (Histatin peptide) having a controlled release over the course of from 1 to 100 days.

Release profiles can be modified by a judicious blend of uncapped and capped polymers either in separate microspheres or in the same microspheres. Release from microcapsule formulations 1 through 21 listed in Table 1, occur independently of each other and hence the cumulative release from blends of these formulations are additive. By blending several formulations of uncapped and end-capped microspheres, release curves of any desired duration can be tailored. In addition, based on the release characteristics of uncapped and end-capped polymers,

5

20

25

blending of the two forms in a single formulation comprising

of the active core thereby providing release curves of any

achieved by the addition of uncapped polymer to end-capped

polymer in amounts as low as 1% up to 100%.

desirable pattern. Manipulation of polymer hydration and

significantly influence the polymer hydration and hence release

degradation resulting in modulation of release of active core is

different ratios of uncapped to capped polymer, would

Table 1- Microcapsule compositions containing Histatin polypeptide

Compositio n#	Polymer	Polymer Description	ď	Theoretic al peptide Core Load (%)	Intern al Phase Ratio (w/o)	Emulsificati on Technique
	L/G Ratio & Type	Mol. Wt.(M w x 10³)	Conc in DCM (w/w			
	05/05 0,0	12	38	S.	1:20	A
	05/05 0,	12	18.5	2	1:20	હ
	20/50	34	10	ស	1:20	æ
	05/05	12	38	ഹ	1:4	æ

<b>E</b>	ш	æ	æ	æ	œ	æ	ш	Ф
1:10	1:10	1:10	1:10	1:10	1:10	1:10	1:10	1:10
വ	w	Ω.	ς.	ហ	ഗ	ស	ហ	2.3
7	10	10	10	23.5	10	7	10	7
34	34	34	12	12	12	12	12	12
50/50	50/50	50/50	75/25	75/25	50/50	50/50	05/05 01/05	50/50 ,U
5.	. 9	7.	ů.	, o	10.	11.	12.	13.

æ	æ	В	В	В	В	В	a a
1:10	1:10	1:10	1:10	1:10	1:10	1:10	1:10
rv	വ	ស	ហ	ហ	ហ	ഥ	5
10	10	10	20	40	ស	10	15
12	34	12	12	12	34	34	34
05/05 0,U	05/05	50/50 U,	05/05	05/05	50/50 , U	05/05	50/50 U
14.	15.	16.	17.	18.	19°.	20.	21.

# Acronyms:

L/G ratio: Copolymer composition of lactide/glycolide DCM: Methylene Chloride Mw: Molecular weight in daltons A: w/o/w emulsification without an intermediate step for emulsion stabilization B: w/o/w emulsification with an intermediate step for emulsion stabilization U: Uncapped polymer

25

5

While referring to Table 1 in conjunction with FIG. 3, it can be seen that the cumulative Histatin release from PLGA microspheres from several batches prepared using 50/50 and 75/25 uncapped and end-capped, polymer modulates release between 1 to 100 days by varying the process parameters. 1-35 days by uncapped 50/50, 18-56 days by capped 50/50 and 56-100 days by capped 75/25.

In referring to FIG. 4, a view is provided through a scanning electron micrograph of PLGA microspheres designed for a one to two month release system prepared using end-capped polymer of Mw 30-40k daltons.

FIG. 5 depicts the cumulative Histatin release from PLGA microspheres, in which the release profiles are from several batches prepared using 50/50, uncapped and capped polymer, and varying the process parameters to modulate release between 28 to 60 days.

Figure 6 represents cumulative Histatin release from PLGA microspheres --- these combined release profiles are from several batches prepared using 50/50 uncapped and capped polymer, and varying the process parameters to modulate release between 1-60 days.

In the context of the invention, a biologically active agent is any water-soluble antibiotics, antitumor agents, antipyretics analgesics, anti-inflammatory agents, antitussives, expectorants, sedatives, muscle relaxants, anti epileptics, antiulcer agents,

30

35

40

5

anti-depressants, anti-allergic drugs, cardiotonics, antiarrhythmics drugs, vasodilators, antihypertensives, diuretics, anticoagulants, hormone drugs, anti-narcotics, etc.

In general, "burst free" sustained release delivery of biologically active agents from PLGA microshperes is accomplished in the context of this invention using of 90/10 to 40/60 molar ratios, and ratios of uncapped polymer to end-capped polymer of 100/0 to 1/99.

In general, the approaches for designing the biologically active agents encapsulated in the uncapped and combination uncapped/end-capped PLGA microspheres and characteristics of these encapsulants are briefly set forth below as follows:

- 1. Providing PLGA microspheres of surface morphologies using 50/50 uncapped and capped polymers of Mw  $\sim 8-40 \rm K$  daltons as shown in Figs. 2 and 4.
- 2. Providing in vitro release of a polypeptide, Histatin from PLGA microspheres, as shown in Figs. 3 and 5, using uncapped and capped polymer of Mw  $\sim$  8-40K daltons and molar ratios such as 50/50 and 75/25.

For example, design of a 1-12 week bioactive compound release system is achieved using PLGA with the following specifications:

1. Polymer molecular weight:
-about 2-60K daltons

2. Copolymer molar ratio (L/G):

- 90/10 to 40/60

3. Polymer end groups:- uncapped and /or end-capped

and combining judiciously within the following parameters:

- 4. Polymer concentration
  - from 5 to 50%
- 5. Inner aqueous to oil phase ratio:
- 1:5 to 1:20 (v/v)
- 6. Peptide loads:
- from 2 to about 40% (w/w polymer)

and by using the unique aqueous emulsification method described in the invention.

The uniqueness and novelty of invention may generally be summarized in a brief way as follows:

- 1. Use of uncapped poly(lactide/glycolide) to achieve burst-free, continuous, sustained, programmable release of biologically active agents over 1-100 days.
- 2. Use of a unique aqueous emulsification system to achieve superior microsphere characteristics such as uniform sphere morphology and narrow size distribution.
- 3. Burst-free, prolonged, sustained release of polypeptides and other biologically actice agents from biocompatible and biodegradable microcapsules up to 100 days in an aqueous physiological environment without the use of additives in the inner core.
- 4. Release of active core programmable for variable durations over 1-100 days by using a blend of uncapped and capped polymer for different molecular weights and copolymer rations and manipulating the process parameters.
- 5. Complete release of the active core concurrent with complete solubilization of carrier polymer to innocuous components such as lactic and glycolic acids, especially when using a 100/0 blend of uncapped/capped polymer. This is of tremendous significance as most biodegradable polymers currently in use for 1-30 day delivery, do not degrade completely at the end of the intended release duration causing serious concern for regulatory authorities on the effects of residual polymer at the site of administration.
- 6. Ease of administration of the microcapsules in various dosages forms via several routes such as parenteral (intramusclar and subcutaneous), oral, topical, nasal, vaginal, etc.

The following examples are illustrative of, but not limitations upon the microcapsule compositions pertaining to this invention.

#### Example\_1

45

50

40

5

10

15

30

Ç.

Carre Carre

ij

₩<u></u>35

Polylactide/glycolide (PLGA) microcapsules are prepared by a unique aqueous emulsification technique which has been developed for use with the uncapped polymer to provide superior sphere morphology, sphere integrity and narrow size distribution (See Figures 1a and 1b). This is accomplished by dissolving the polymer in a chlorinated hydrocarbon solvent such as methylene chloride and dissolving the biologically active agent in water. A

w/o emulsion is then formed by mixing the solutions of polymer and the active agent by sonication, followed by emulsion stabilization in a solvent - saturated aqueous solution containing polyvinyl alcohol. A ternary emulsion is then formed by emulsifying the w/o emulsion in an external, pre-cooled aqueous phase containing polyvinyl alcohol (0.25 - 1% w/v). Microcapsules are hardened upon removal of solvent by evaporation, rinsed to remove any residual emulsifier, and then lyophilized.

10

15

23

T.

E CE

35

**30** 

5

Table 1 lists the microcapsule compositions, Nos. 1-21 thus prepared, consisting of a biologically active polypeptide, Histatin (composed of 12 amino acids and a molecular weight of 1563) and blends of uncapped and capped polymer of ratios 100/0 to 1/99, and having a lactide/glycolide ratio of 90/10 to 40/60, and a molecular weight range between 2000 to 60,000 daltons.

Example 2

Microcapsule compositions are prepared as described in Example 1 wherein the copolymer L/G ratio is 48/52 to 52/48, and the ratio of uncapped/capped polymer is 100/0. The active core is Histatin (Mw 1563), the polymer molecular weight is < 15,000 and the polymer concentrations vary from 7% to  $\sim$  40% w/w. Compositions 1,2,4 12-14 and 16-18 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment, such as phosphate-buffered saline, pH 7.0 maintained at 37  $\pm$  1°C are plotted as cumulative percentage release versus time, and presented in Figure 2.

Burst-free, variable release from 1-35 days is achieved by varying the polymer concentration from 7 to ~ 40% w/w in the oil phase.

40

Example 3

Microcapsule compositions are prepared as described in Example 2, wherein the aqueous /oil ratio is varied from 1/4 to 1/20 (v/v). Compositions 1,2,4 and 12 are listed in Table 1.

45

Release profiles of the active core from the compositions in an aqueous physiological environment described in Example 2 are plotted as cumulative percentage release versus time, and presented in Figure 2.

50

Burst-free, continuous release from 1-35 days, with different onset and completion times are achieved by selecting

different w/o ratios in the inner core.

5

10

15

₫ 35

40

50

# Example 4

Microcapsule compositions are prepared as described in Example 2, wherein the polymer molecular weight is 28,000-40,000 and polymer concentrations vary from 5% to ~ 15% w/w. Compositions 19-21 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2 are plotted as cumulative percentage release versus time and presented in Figure 3.

Burst-free, variable release from 18-40 days is achieved by varying the polymer concentration.

#### Example 5

Microcapsule compositions are prepared as described in Example 2, wherein the ratio of uncapped/capped polymer is 1/99 and polymer concentrations vary between 5% to ~ 12% w/w. Compositions 10 and 11 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2, and plotted as cumulative percentage release versus time and presented in Figure 2.

Burst-free, variable release from 28-70 days is achieved by varying the polymer concentration in the oil phase.

## Example 6

Microcapsule compositions are prepared as described in Example 5, wherein polymer molecular weight is 28,000-40,000 and polymer concentrations vary between 5% to ~ 12% w/w. Compositions 5 and 6 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2 and are plotted as cumulative percentage release versus time, and presented in Figure 3.

Burst-free, variable release from 28-70 days is achieved by varying the polymer concentration.

#### Example 7

Microcapsule compositions are prepared as described in Example 6, wherein the aqueous/oil ratio varies between 1/5 to

1/25 (v/v). Compositions 3 and 7 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2, and plotted as cumulative percentage release versus time, and presented in Figure 3.

Burst-free, variable release from 28-70 days is achieved by varying the aqueous/oil ratios.

10

15

B:

1

IJ

E.

Ţ

ű

35

30

5

# Example 8

Microcapsule compositions are prepared as described in Example 5, wherein the copolymer ratio is 75/25 and polymer concentrations vary between 5% to ~ 25% w/w. Compositions 8 and 9 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2, and are plotted as cumulative percentage release versus time, and presented in Figure 2.

Burst-free, variable release from 56->90 days is achieved by varying the polymer concentration in the oil phase.

# Example 9

Microcapsule compositions are described in Example 2, wherein the active core is leutinizing hormone releasing hormone (LHRH, a decapeptide of molecular weight 1182) and the polymer concentration is ~40% w/w. Release profiles of the active core from the composition in an aqueous physiological environment is described in Example 2, and is plotted as cumulative percentage release versus time, and presented in Figure 4.

Burst-free, continuous and complete release is achieved within 35 days, similar to Histatin acetate.

40

45

50

#### Example 10

Microcapsule compositions are prepared as described in Example 2, wherein an additive such as sodium salt (carbonate or bicarbonate) is added to the inner aqueous phase at concentrations of 1-10% w/w to maintain the biological activity of the released polypeptide.

Burst-free, variable release from 1-28 days is achieved similar to Examples 2 & 3, and the released polypeptide is biologically active until 30 days, due to the presence of the sodium salt.

## Example 11

Microcapsule compositions are prepared as described in Example 2, wherein an additive such as a nonionic surfactant, polyoxyethylene/polyoxypropylene block copolymer (Pluronics F68 and F127) is added to either the inner oil or the aqueous phase at concentrations from 10-100% w/w, to maintain the biological activity of the released polypeptide.

10

5

Burst-free, continuous release from 1-35 days is achieved similar to Examples 2 & 3, and the released polypeptide is bioactive due to the presence of the surfactant.

15

# Example 12

Cumulative histatin release from the microcapsule compositions described in Examples 1 through 11 and release profiles plotted in Figures 2 and 3 show the burst-free, programmable peptide release for variable duration from 1-100 days. Virtually any pattern of cumulative release is achievable over a 100 day duration by a judicious blending of several compositions, as shown in these figures.

35

J

40

45

50

25

5

#### WE CLAIM

1

- 1. A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a biologically active agent over a duration from 1-100 days, comprising an active agent and a blend of uncapped and end-capped biodegradable poly(lactide/glycolide).
- 2. The pharmaceutical formulation of claim 1, wherein the biodegradable poly(lactide/glycolide) is a blend of uncapped and capped forms, in ratios ranging from 100/0 to 1/99.
- 3. The microcapsules of claims 1 or 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and endcapped polymer is 52/48 to 48/52.
- 4. The microcapsules of claims 1 or 2 wherein the copolymer L/G ratio for uncapped and end-capped polymer is 90/10 to 40/60.
- 5. The microcapsules of claim 3 wherein the molecular weight of the copolymer is between 2,000-60,000 daltons.
- 6. The microcapsules of claim 1 wherein the biologically active agent is a peptide or polypeptide.
- 7. The microcapsules of claim 6, wherein said polypeptide is histatin consisting of 12 amino acids and having a molecular weight of 1563.
- 8. The microcapsules of claim 7 characterized by the capacity to completely release histatin in an aqueous physiological environment from 1-35 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G

25

5

ratio of 48/52 to 52/48, and a molecular weight <15,000.

- 9. The microcapsules of claim 7 characterized by the capacity to completely release histatin in an aqueous physiological environment from 18-40 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 28,000-40,000.
- 10. The microcapsules of claim 7 characterized by the capacity to release up to 90% of the histatin in an aqueous physiological environment from 28-70 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 10,000-40,000 daltons.
- 11. The microcapsules of claim 7 characterized by the capacity to release up to 80% of histatin in an aqueous physiological environment from 56-100 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 75/25 and a molecular weight of < 15,000 daltons.
- 12. The microcapsules of claims 7 or 8 or 9 or 10 or 11 having analogs of histatin with chain lengths of from 11-24 amino acids of molecular weights from 1,500-3,000 daltons and characterized by the following structures:
  - 1. D S H A K R H H G Y K R K F H E K H H S H R G Y
  - 2. KRHHGYKRKFHEKHHSHRGYR
  - 3. KRHHGYKRKFHEKHHSHR
  - 4. RKFHEKHHSHRGYR

25

5

- 5. AKRHHGYKRKFH
- 6. \*AKRHHGYKRKFH
- 7. KRHHGYKRKF
- \* D-amino acid
- 13. The microcapsules of claim 6 wherein the biologically active agent is a polypeptide Leutinizing hormone releasing hormone (LHRH) that is a decapeptide of molecular weight 1182 in its acetate form, and having the structure:

# p-EHWSYGLRPG

- 14. The microcapsule of claim 6 having a molecular weight of from 1,000 to 250,000 daltons.
- 15. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 wherein release profiles of variable rates and durations are achieved by blending uncapped and capped microspheres as a cocktail in variable amounts.
- 16. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 wherein release of profiles of variable rates and duration are achieved by blending uncapped and capped polymer in different ratios within the same microshreres.
- 17. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 wherein the entrapped polypeptide is any of the vaccine agents against enterotoxigenic E. coli (ETEC) such as CFA/I,CFA/II,CS1,CS3,CS6 and CS17 and other ETEC-related enterotoxins.

25

5

- 18. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 13 or 14 wherein the entrapped polypeptide consists of peptide antigens of molecular weight range of about 800-5000 daltons for immunization against enterotoxigenic E. coli (ETEC).
- 19. The microcapsules of claims 1 or 2 or 3 or 4 or 5 wherein said biologically active agents are selected from the group consisting of water-soluble hormone drugs, antibiotics, antitumor agents, anti inflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, and antinarcotics, in the molecular weight range of 100-100,000 daltons.
- 20. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 wherein said biodegradable poly(lactide/glycolide) is in an oil phase, and is present in about 1-50% (w/w).
- 21. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14 wherein concentration of the active agent is in the range of 0.1 to about 60% (w/w).
- 22. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14 wherein a ratio of the inner aqueous to oil phases is about 1/4 to 1/40(v/v).
- 23. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising: Dissolving

biodegradable poly (lactide/glycolide), in uncapped form in methylene chloride, and dissolving a biologically active agent or active core in water; adding the aqueous layer to the polymer solution and emulsifying to provide an inner water-in-oil (w/o) emulsion; stabilizing the w/o emulsion in a solvent-saturated aqueous phase containing a oil-in-water (o/w) emulsifier; adding said w/o emulsion to an external aqueous layer containing oil-in-water emulsifier to form a ternary emulsion; and stirring the resulting water-in-oil-in-water (w/o/w) emulsion for sufficient time to remove said solvent, and rinsing hardened microcapsules with water and lyophilizing said hardened microcapsules.

24. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising:

dissolving biodegradable poly(lactide/glycolide) in endcapped form in methylene chloride, and dissolving a biologically
active agent or active core in water; adding the aqueous layer to
the polymer solution and emulsifying to provide an inner waterin-oil emulsion; stabilizing the w/o emulsion in a solventsaturated aqueous phase containing a oil-in-water (o/w)
emulsifier; adding said w/o emulsion to an external aqueous layer
containing oil-in-water emulsifier to form a ternary emulsion;
and stirring a resulting water-in-oil-water (w/o/w) emulsion for
sufficient time to remove said solvent; and rinsing hardened
microcapsules with water; and lyophilizing said hardened
microcapsules.

25

5

- 25. The process of claims 23 or 24 wherein a solvent-saturated external aqueous phase is added to emulsify the inner w/o emulsion prior to addition of the external aqueous layer, to provide microcapsules of narrow size distribution range between  $0.05-500\mu m$ .
- 26. The process of claims 23 or 24, wherein a low temperature of about 0-4°C is provided during preparation of the inner w/o emulsion, and a low temperature of about 4-20°C is provided during preparation of the w/o/w emulsion to provide a stable emulsion and high encapsulation efficiency.
- 27. The process of claim 23 wherein a 100/0 blend of uncapped and end-capped polymer is used to provide release of the active core in a continous and sustained manner without a lag phase.
- 28. The microcapsules of claim 6, wherein, when the entrapped polypeptide is active at a low pH, such as LHRH, adrenocorticotropic hormone, epidermal growth factor, calcitonin released polypeptide is bioactive.
- 29. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11, wherein, when entrapped peptide such as histatin is inactive at a low pH, a pH-stabilizing agent of inorganic salts are added to the inner aqueous phase to maintain biological activity of the released peptide.
- 30. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 wherein, when entrapped polypeptide such as histatin is inactive at a low pH, a non-ionic surfactant such as polyoxyethylene

20

25

5

sorbitan fatty acid esters (Tween 80, Tween 60 and Tween 20) and polyoxyethylene - polyoxypropylene block copolymers (Pluronics) is added to the inner aqueous phase to maintain biological activity of the released polypeptide.

- 31. The microcapsules of claim 29, wherein placebo spheres loaded with the pH-stabilizing agents are coadministered with polypeptide-loaded spheres to maintain the solution pH around the microcapsules and preserve the biological activity of the released peptide in instances where the addition of pH-stabilizing agents in the inner aqueous phase is undesirable for the successful encapsulation of the acid pH sensitive polypeptide.
- 32. The microcapsules of claim 30 wherein placebo spheres loaded with non-ionic surfactant are coadministered with polypeptide-loaded spheres to maintain biological activity of the released peptide where the addition of non-ionic surfactants in the inner aqueous phase is undesirable for successful encapsulation of the acid pH sensitive polypeptide.
- 33. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14 comprising a blend of uncapped and capped polymer, wherein complete solubilization of the copolymer leaves no residual polymer at the site of administration and occurs concurrently with the complete release of the entrapped agent.
- 34. A process of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13 or 14 for human

administration via parenteral routes, such as intramuscular and subcutaneous.

- 35. A process of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via topical route.
- 36. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via oral routes.
- 37. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via nasal, transdermal, rectal, and vaginal routes.

20

25

#### Abstract

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.




Fig. 1




Fig. 2





Figure 201









Fig. 4

ŧ





Release of LHRH from PLGA microspheres



	Associate Power Of Attorney Or Agent (37 CFR 1.34) (For Representation Related To A Patent Application)							
Re Application Of: Jeg	yenthi, et al.							
Serial No.	Filing Date Jensery 24, 1996	Examiner Harrison, R.	Group Art Unit					
	TO THE ASSISTANT CO	MMISSIONER FOR PATENTS:						
lease recognize the follo	TO THE ASSISTANT CO		In this epplication.					
ease recognize the follo	_	sy 🔲 Associate Agent						
·	wing as 🖾 Associate Attorne	sy 🔲 Associate Agent						
Re	wing as  Associate Attorne Name: Mariesa Titus and Ca	sy   Associate Agent  areitse Nash  spectively						
Re	Name: Mariesa Titus and Cang. No.: 35,843 and 36,329, residence: PLEASE CHANGE CADDRESS TO: Nash & Titus, LEC	Associate Agent  aretise Nash  pectively  CORRESPONDENCE						
Re	Name: Mariesa Titus and Ca sq. No.: 35,843 and 36,329, res doress: PLEASE CHANGE C ADDRESS TO:	Associate Agent  aretise Nash  pectively  CORRESPONDENCE						
Re	Name: Mariana Titus and Cang. No.: 35,843 and 34,329, residence: PLEASE CHANGE CADDRESS TO:  Nash & Titus, LLC 3415 Brookeville Resi	Associate Agent  areline Nash  pectively  CORRESPONDENCE						

Signature of Principal Attorney or Agent of Record

Werten F.W. Bellamy, Reg. No. 27, 029 Intellectual Property Law Division OTJAG, Department of the Army 901 North Stuart Street

Aritugton, VA 22203-1837

Registration Number & Address of Principal Assormes or Agent of Record

Deted: 5/6/99

Contify that this document is being deposited on 5-11-95 with the U.S. Postal Bervice as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Weshington, D.C. 20231.

Signature of Person Melling Correspondence

Product Prince Name of Prince Market Commendation

ne/			/ ~	
li <sub>to</sub> hE(	CLARATION FOR PATENT		•	ke: Nymber (Optional)
	I hereby deciz at: Ramasubbu lonald Roberes, Charles E. dress and citizenship are as stated b		A. Jetterstr	t, Phil Friden, om
I believe I am the original, fin names are listed below) of th Novel Burst-Free	st and sole inventor (if only one name subject matter which is claimed an Sustained Release Poly (I	s is listed below) or an d for which a patent is actide/Glycolid	onginal, first and it sought on the inve e), the s	pint inventor (if plural intion entitled perfication of which
Microspheres is attached hereto unless the				
$\mathbf{x}$ was filed on $1/24/96$		plication Number or Po		
Number <u>08/590,9</u>	and was amended o	ı	(# &	pplicable).
amended by any amendment	iewed and understand the contents of treferred to aboye. close information which is material to		•	
I hereby daim foreign priority inventor's certificate listed be	benefits under Title 35, United State low and have also identified below as at of the application on which priority	ry foreign application fo	e)nøtspilogs.ngjero omeyni ochnetse v	s) for patent or r's certificate
Prior Foreign Application(s)	•			Promity Claimed
				☐ Yes ☐ No
(Number)	(County)	(Day/Month/Year	Filed)	□-Yeş □ No
(Number)	(County)	(Day/Month/Year		Yes No
(Number)	(Country)	(Day/Month/Year	Føęd)	
(Application Number)	e national or PCT international filing of (Filing Date)		(Status – patiented	pending, scandoned)
(Application Number)	(Fing Date)		(Status – patented	pending, abandoned)
Patent and Trademark Office of	attorney(s) and/or agent(s) to prosect connected therewith: Earl T. Re W. Randolph, Reg #28,986	ichert, Reg #24,	331; Werten	F.W. Bellamy
Address all telephone calls to	TIMEL FORUM DROPERS		ber.	
Address all correspondence to	OFFICE OF THE JUDGE ADV		DA	
	901 NORTH STUART STREET			
	ARLINGTON, VA 22203-18	37		,
belief are believed to be true; a	ents made herein of my own knowled nd further that these statements were	made with the knowled	ge that willful false	
such willful false statements ma Full name of first invent	fine or imprisonment, or both, under by jeopardize the validity of the application of the application of the application of the properties of the control of	ation or any patent issu-	ed thereon.	
such willful false statements ma Full name of first invent first inventor signatur Residence 1725 ctcck	tine or imprisonment, or both, under by jecpardize the validity of the applic or (given name) family name) Rame COLU	MPIA MD 21046	od thereon. Date 05 24	
Full name of first invent first inventor signatur Residence 9725 CLCCK Post Office Address 9725	tine or imprisonment, or both, under by jecpardize the validity of the applic or (given name) family name) Rame (A) TONER LANE #301 COLUCTONER LANE	acubbu Jevanthi	od thereon. Date 05 24	es Code and that
Full name of first invent first inventor signatur Residence 9725 200K	tine or imprisonment, or both, under by jecpardize the validity of the applic or (given name) family name) Rame COLU	asubbu Jevanthi MBIA MD 21044 APT # 301	od thereon. Date 05 24	es Code and that
Full name of first invent first invent first inventor signatur.  Residence 9725 660 K  Post Office Address 9725  Full name of - doint inventor.	fine or imprisonment, or both, under by jeopardize the validity of the application (given name) Rame (Rame) Rame (	asubbu Jevanthi MBIA MD 21044 APT # 301	Date 05 24 Citizenship 1	es Code and that
Full name of first invent first invent first inventor signatur.  Residence 9725 610 K  Post Office Address 9735  COLO  Full name of doint inventor.	fine or imprisonment, or both, under my jeopardize the validity of the applicant (given name) family name). Rame CLOCKTONER LAME (TONER LAME IMBIA MD 21046 tor, if any (given name, family name)	asubbu Jévanthi MBIA MD 21044 APT #301	Date 05 24 Chizenship 1	es Code and that
Full name of first invent first invent first inventor signatur.  Residence 1725 CLCCK  Post Office Address 9725  COLC  Full name of doint inventor.	fine or imprisonment, or both, under by jeopardize the validity of the application (given name). Rame (given name) From the COLUCTONER LANE HAD 210 46 for, if any (given name, family name)	asubbu Jévanthi MBIA MD 21044 APT #301	Date 05 24 Citizenship 1	es Code and that

#### Dooxst Number (Optional) DECLARATIO FOR PATENT APPLICATION As a below named inventor, I hereby declare that: Ramasubbu Jeyanthi, John E. an Hamont, Phil Friden, Robert H. Reid, F. Donald Roberts, Charles E. McQueen, Jean A. Setterstrom My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Novel Burst-Free Sustained Release Poly (Lactide/Glycolide) the specification of Microspheres is attached hereto unless the following box is checked: x was filed on 1/24/96 as United States Application Number or PCT International Application Number 08/590,973 and was amended on \_ I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby daim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Priority Claimed Prior Foreign Application(s) ☐ Yes ☐ No (Day/Mont/Year Fied) (County) (Number) ☐ Yes ☐ No (Day/Montt/Year Field) J (Number) (Country) ☐ Yes ☐ No (Day/Month/Year Faed) (Number) (County) higher oby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is patental to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the firing date material to patentability as defined in Title 37, 000000, on an armound of the application. of the prior application and the national or PCT international filing date of this application. (Status - parented, pending, spandoned) (Application Number) (Fring Date) (Status - parented pending abandoned) (Application Number) (Fing Date) Thereby appoint the following amorney(s) and/or agent(s) to prosecute this application and to transact all business in the From and Trademark Office connected therewith; Earl T. Reichert, Reg #24,331; Werten F.W. Bellamy Reg #27,029; William W. Randolph, Reg #28,986; Maj Murray B. Baxter, Reg #33,646 Address all telephone calls to at telephone number INTELLECTUAL PROPERTY LAW DIVISION :Address all correspondence to \_ OFFICE OF THE JUDGE ADVOCATE GENERAL, DA 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Tale 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Full name of second inventor (given name, family name) Residence 7446 VAN NOY LOOP FORT MERDE MD. 20753 Citizanship <u>USA</u> Post Office Address 7446 VAN NOY LOOP FORT MEADE, MO. 20755 Full name of secondoint inventor, if any (given name, family name) \_ \_ Date \_ Citizenship Residence.

Additional inventors are being named on separately numbered sheets attached hereto. page 2 of 7

Post Office Address

2	DE	CLARATION	1 FOR PATEN	AFFLICATION	•	سره ، دد وبي
As a	a below named inventor,	. I hereby deck	հat: Ramasubbu	Jeyanthi, John	E. mont. H	hil Friden,
Rol My r	bert H. Reid, F. residence, postoffice ad	Donald Rober Idress and chizen	rts, Charles E nship are as stated b	. McQueen, Jean	A. setterst	rom
l bei	lieve I am the original, fires are listed below) of the vell Burst-Free	rst and sole inver	ntor (if only one nam	ne is listed below) or ar	n original, first and s sought on the in	d joint inventor (if plu vention entitled
Mic	crospheres	Justailled Ke	rease rolly (rac	ride/Giacolide)	• • • • • • • • • • • • • • • • • • • •	specification of whi
is at	ttached hereto unless th	e tollowing box is	checked;			
X	was filed on 1/24/96	6		pplication Number or F	CT International	Application
	Number 08/590,9	73	and was amended o	n	<b>(</b> fi	applicable).
l ber	eby state that I have rev	iousd and under	mined the meteric	of the shove Heatified	specification incl	voice the el-ime
	nded by any amendmen			DI MIN ALOVA KAMMINE	عبدان المحادث	comp the cizilis, Es
	nowledge the duty to dis			o patentability as defin	ed in Title 37, C∞	de of Federa!
Regu	ulations, § 1.56.			•		_
inver	eby daim foreign priority nton's certificate listed be ng a filling date before th	bw and have als	a wded beitinebi ca	ny foreign application f		
		a. Ci tiie appikali	on on which priority	D CLEMBC.		Priority Claime
	Foreign Application(s)					Yes No
	(Number)	(Cour	ntry)	(Day/Mont/Yea	Fied)	[] LES [] NO
			•			Yes No
	(Number)	(Caur	יביץ)	(Day/Mont/Yea/	Filed)	D Vee Date
2011	(Number)			(Day/Mont/Year	Fied)	☐ Yes ☐ No
	,	(Cau	· · · · · · · · · · · · · · · · · · ·	() · · · · ·	•	
Libered the provide the provident to the	by daim the beneficiand a subject matter of each ded by the first paragraphial to patentability as delight prior application and the	ler Trile 35, United of the claims of th hio! Trile 35, United tined in Trile 37, C	d States Code, § 120 his application is not ed States Code, § 1 Dode of Federal Feg	C of any United States displayed in the prior L 12, I advinced to the state of the	United States appli duty to disclose in	lication in the manne formation which is
There the	by claim the beneficiand authors matter of each ded by the first paragraphial to patentability as del	ler Trile 35, United of the claims of th hio! Trile 35, United tined in Trile 37, C	d States Code, § 120 his application is not ed States Code, § 1 Dode of Federal Feg	C of any United States displayed in the prior L 12, I advinced to the state of the	United States appi duty to disclose in became available	leaten in the manne formation which is between the filing d
There the	by daim the beneficiand a subject matter of each ded by the first paragraphial to patentability as definition and the prior application and the aton humber;	ler Trile 35, United of the claims of th hio! Trile 35, United tined in Trile 37, C	d States Code, § 123 his application is not ed States Code, § 1 Dode of Federal Fleg international filing d	C of any United States displayed in the prior L 12, I advinced to the state of the	United States application to disciple and available common available (State - pareness)	leaten in the manne formation which is between the filing d d, pending scandoned
Who had a second and a second a	by daim the benefit and a subject matter of each ded by the first paragraphial to patentability as delipidor application and the aton Number)	for Title 35, United of the claims of the highest United fined in Title 37, Control of mational or PCT	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Reg imemational filing d  (Fang Date)	O of any United States disclosed in the prior last nowledge the sulfations, § 1.56 which late of this application.	United States application to discover in discover in became available  (Status - patential  (Status - patential	lication in the manner formation which is between the filling did not between the filling abandoned.
Libered Liberal Libered Liberal Libera	by claim the benefit und a subject matter of each ded by the first paragraphial to patentability as del prior application and the aton Number) abon Number)	for Title 35, United of the dialms of the dialms of the dialms of the dial of	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Registremational filing d  (Fing Date)  (Fing Date)	O of any United States disclosed in the prior L. 12, I advisor whedge the sulmines, § 1.56 which late of this application.	United States applicable to transact all has	lication in the manni- formation which is between the filling of d, pending shandoned I pending shandoned liness in the
The the control of th	by daim the beneficiand aubject matter of each ded by the first paragraphial to parentability as deligible prior application and the aton Number) abon Number) by appoint the following and Trademark Office of 24,331; Werten Furray B. Baxter.	for Title 35, United of the dialms of the dialms of the dialms of the dial of	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Registremational filing d  (Fing Date)  (Fing Date)	Octany United States discosed in the prior last new force of the state of this application and William W. Rand	United States applied by the disciplination in the common available (State - parented (State - parented to transact all bus Learl T. olph, Reg #2	leaten in the manniformation which is between the filing of dispending shandoned pending shandoned iness in the Reichert, 8,986;
The the control of th	by claim the beneficiand a subject matter of each field by the first paragraphial to patentability as defined to patentability as defined to prior application and the aton humber) by appoint the following a and Trademark Office of 24,331; Werten Flurray B. Baxter, as all telephone calls to	ler Trile 35, United of the claims of the cl	d States Code, § 126 his application is not ed States Code, § 1 Dode of Federal Fierg (memational filling d  (Fang Date)	or any United States discoved in the prior by 12, I acknowledge the sulminess § 1.56 which late of this application and William W. Rand	United States applied by the disciplination in the common available (State - parented (State - parented to transact all bus Learl T. olph, Reg #2	leaten in the manner formation which is between the filing did pending shandoned iness in the Reichert, 8,986;
The the tree the tree that the tree tree that the tree tree tree tree tree tree tree	by daim the beneficiand aubject matter of each ded by the first paragraphial to parentability as deligible prior application and the aton Number) abon Number) by appoint the following and Trademark Office of 24,331; Werten Furray B. Baxter.	ter Trie 35, United of the claims of the cla	d States Code, § 126 his application is not ed States Code, § 1 Code of Federal Reg imemational filing d  (Fing Date)	C of any United States discoved in the prior by 12, I sownowledge the submissions, § 1.56 which late of this application and William W. Rand at telephone number 1975 and DIVISION	United States applied by the disciples in the transact all bus Earl T. olph, Reg #2	leaten in the manner formation which is between the filing did pending shandoned iness in the Reichert, 8,986;
the to the transfer of the tra	by claim the beneficiand a subject matter of each field by the first paragraphial to patentability as defined to patentability as defined to prior application and the aton humber) by appoint the following a and Trademark Office of 24,331; Werten Flurray B. Baxter, as all telephone calls to	ter Trie 35, United of the diaims of the diaims of the diaims of the diams of the d	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing d  (Firing Date)  (Firing Date)  (Firing Date)  Reg #27,029;  UAL PROPERTY L THE JUDGE ADV	C of any United States discoved in the prior be 12. I sownewiedge the sulmines, § 1.56 which are of this application and William W. Rand  at telephone number of the prior be supplied in the prior be applied in the prior be applied in the best applied in the prior best applied in the best applied in th	United States applied by the disciples in the transact all bus Earl T. olph, Reg #2	leaten in the manner formation which is between the filing did pending shandoned iness in the Reichert, 8,986;
The the tree the tree that the tree tree that the tree tree tree tree tree tree tree	by claim the beneficiand a subject matter of each field by the first paragraphial to patentability as defined to patentability as defined to prior application and the aton humber) by appoint the following a and Trademark Office of 24,331; Werten Flurray B. Baxter, as all telephone calls to	ter Trie 35, United of the diaims of the diaims of the diaims of the diams of the d	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing d  (First Date)	or any United States discissed in the prior bits application and william W. Rand  at telephone numination of the prior bits application and william W. Rand  State of this application and william W. Rand  State of the phone numination of the prior of the phone numination	United States applied by the disciples in the transact all bus Earl T. olph, Reg #2	leaten in the manner formation which is between the filing did pending shandoned pending shandoned iness in the Reichert, 8,986;
the control of the co	by daim the beneficiand a subject matter of each ded by the first paragraphial to patentability as defined to patentability as defined to patentability as defined and the prior application and the aton Number) aton Number) by appoint the following than 31; Werten Figuriay B. Baxter, as all telephone calls to as all correspondence to	etcrney(s) and/or marked the marked to the claims of the c	d States Code, § 123 his application is not ed States Code, § 1 Dode of Federal Fieg imemational filing of  (Fing Date)  (Fing Date)  (Fing Date)  (Application is not ed States Code, § 1 Dode of Federal Fieg imemational filing of  (Fing Date)  (Fing Date)  (Fing Date)  (Application is not ed States Code, § 123  (Fing Date)	of any United States discoved in the prior by 12, I acknowledge the sulminess \$ 1.56 which late of this application and William W. Rand witelephone number 15 and 1	United States applied by the disclose in became available  (State - patented (States - patented to transact all bus Earl T. olph, Reg #2 ber	leaten in the manniformation which is between the filing of dispending shandoned iness in the Reichert, 8,986;
The to the control of	by claim the beneficiand a subject matter of each ded by the first paragraphial to potentiability as deligible prior application and the aton humber) by appoint the following than Trademark Office of 24,331; Wenten Flurray B. Baxter, as all telephone calls to as all correspondence to be deduced to be true; are believed to be true; are	er Trie 35. United of the claims of the clai	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Fieg international filting of  (Fing Date)  (Fing Date)	c of any United States discoved in the prior bits application and william W. Rand at telephone number of the SUITE 700 37 se are true and that all a made with the knowled	United States applied by the disciples in the disciples in the disciple in the	ication in the manniformation which is between the filing did pending shandoned pending shandoned iness in the Reichert, 8,986;
The to the control of	by claim the beneficiand a subject matter of each ded by the first paragraphial to potentiability as defined by the first paragraphial to potentiability as defined by appoint the following a subject to the following of the first paragraphic filters of the filte	etcrney(s) and/or material the diams of the claims of the	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing of  (Firing Date)	or any United States discoved in the prior be 12. I acknowledge the sulmions, § 1.55 which late of this application and William W. Rand with the prior be 15 application and Sulff General, Sulff 700 37 are true and that all smade with the knowled section 1001 of Tale 18	United States applied by the disclose in became available  (State - patented  (State - pa	leaten in the manniformation which is between the filing of detections abandoned pending abandoned iness in the Reichert, 8,986;
Address hereby with the policy and t	by daim the beneficiand audion mater of each ded by the first paragraphial to parentability as defined by the first paragraphial to parentability as defined by appoint the following auton humber)  by appoint the following and Trademark Office of 24,331; Werten Flurray B. Baxter, as all telephone calls to as all correspondence to be decired to be true; ar made are punishable by liftful false statements may	etcrney(s) and/or enterney(s) an	d States Code, § 123 his application is not ed States Code, § 1 Dode of Federal Flog international filing of  (Firig Date)	c of any United States discissed in the prior bits of this application and william W. Rand  at telephone number of the SUITE 700  37  be are true and that all a made with the knowled section 1001 of Tate 18 tion or any patent issue.	United States applied by the disclose in became available  (State - patented  (State - pa	ication in the manner formation which is between the filing did pending shandoned pending shandoned iness in the Reichert, 8,986;
Address with the full name of the full n	by claim the beneficiand audioc matter of each ded by the first paragraphial to parentability as defined by the first paragraphial to parentability as defined by appoint the following the tank (Trademark Office of 24,331; Werten Flurray B. Baxter, as all telephone calls to as all correspondence to be true; are believed to be true; are made are punishable by liftful false statements may me of third inventor.	et Trie 35. United of the claims of the clai	d States Code, § 123 his application is not ed States Code, § 1 Dode of Federal Flog international filing of  (Firig Date)	c of any United States discissed in the prior bits of this application and william W. Rand  at telephone number of the SUITE 700  37  be are true and that all a made with the knowled section 1001 of Tate 18 tion or any patent issue.	United States applied by the disclose in became available  (State - parents)  (State - parents)  (State - parents)  to transact all bus  Earl T.  olph, Reg #2  ber  DA  statements made all ge that willful false of the United State and thereon.	ication in the manner formation which is between the filling of dipending standard formation and the statements and that
the control of the co	by daim the beneficiand aubject matter of each ded by the first paragraphial to parentability as defined by the first paragraphial to parentability as defined by the prior application and the prior application and the aton humber) aton humber) by appoint the following the and Trademark Office of 24,331; Werten Flurray B. Baxter. It is all telephone calls to as all correspondence to a sall correspondence to the believed to be true; ar made are punishable by the first are punishable by the first are punishable to the statements may me of third inventor signature.	et Trie 35. United of the claims of the clai	d States Code, § 123 his application is not ed States Code, § 1 Dode of Federal Flog international filing of  (Firig Date)	c of any United States discoved in the prior by 12, I acknowledge the sulmines, § 1.55 which late of this application and William W. Rand witelephone number of the prior of the Sulfer 700 37 see are true and that all semade with the knowled section 1001 of Tale 18 tion or any patent issue Friden	United States applied by the disclose in became available  (State - patented  (State - pa	leation in the manner formation which is between the filing did pending standoned pending standoned iness in the Reichert, 8,986;  on information and a statements and the es Code and that
there is the control of the control	abor Number)  and Trademark Office of and Trademark Office of Sall telephone calls to as all correspondence to the believed to be true; ar made are punishable by the first paragraphic properties of third inventor signature.	etcrney(s) and/or enterney(s) an	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing of  (Firing Date)  (Fi	c of any United States discoved in the prior by 12, I acknowledge the sulmines, § 1.55 which late of this application and William W. Rand witelephone number of the prior of the Sulfer 700 37 see are true and that all semade with the knowled section 1001 of Tale 18 tion or any patent issue Friden	United States applied by the disclose in became available  (State - parents)  (State - parents)  (State - parents)  to transact all bus  Earl T.  olph, Reg #2  ber  DA  statements made all ge that willful false of the United State and thereon.	leation in the manner formation which is between the filling did pending shandoned pending shandoned iness in the Reichert, 8,986;  on information and a statements and the es Code and that
Address the full name of the first of the fi	by claim the beneficiand a subject matter of each ded by the first paragraphial to parentability as defined by the first paragraphial to parentability as defined by the prior application and the prior application and the prior application and the prior application for a subject to the prior application for a subject to the prior application and the prior application for application and the first and trademark Office of 24,331; Wenten Furnay B. Baxten. It is all the prior and the prior and are punishable by the prior application and third inventor are punishable by the prior and the prior application and the prior applications. The prior application and the prior applications are punishable by the first are punishable by the first are punishable by the prior applications. The prior applications are punishable by the first are punishable by the prior applications are punishable by the prior applications. The prior applications are punishable by the prior applications are punishable by the prior applications.	etcrney(s) and/or enterney(s) and en	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing of  (Firing Date)  (Fi	c of any United States discoved in the prior be 12. I acknowledge the subminers, § 1.56 which late of this application and William W. Rand with the prior be are true and that all made with the knowled section 1001 of Tale 18 tion or any patent issue Friden	United States applied by the disclose in became available  (State - patented  (State - pa	leation in the manner formation which is between the filing did pending standoned pending standoned iness in the Reichert, 8,986;  on information and a statements and the es Code and that
Address the full name of the first of the fi	by claim the beneficiand a subject matter of each ded by the first paragraphial to parentability as defined by the first paragraphial to parentability as defined by the prior application and the prior application and the prior application and the prior application for a subject to the prior application for a subject to the prior application and the prior application for application and the first and trademark Office of 24,331; Wenten Furnay B. Baxten. It is all the prior and the prior and are punishable by the prior application and third inventor are punishable by the prior and the prior application and the prior applications. The prior application and the prior applications are punishable by the first are punishable by the first are punishable by the prior applications. The prior applications are punishable by the first are punishable by the prior applications are punishable by the prior applications. The prior applications are punishable by the prior applications are punishable by the prior applications.	etcrney(s) and/or enterney(s) and en	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing of  (Firing Date)  (Fi	c of any United States discoved in the prior be 12. I acknowledge the subminers, § 1.56 which late of this application and William W. Rand with the prior be are true and that all made with the knowled section 1001 of Tale 18 tion or any patent issue Friden	United States applied by the disclose in became available  (State - patented  (State - pa	ication in the manner formation which is between the filing did pending standoned pending standoned iness in the Reichert, 8,986;  on information and a statements and the es Code and that
the to the control of	as all correspondence to be five dealer that all statements may declare that all statements may declare that all statements may declare that all statements may me of third inventor signature needs to be true; are point of third inventor signature needs to be true; are point of third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be points and third inventor signature needs to be points and third inventor signature needs to be points and the points and the points are points and the points and the points are points are points and the points are points and the points are points are points and the points are points. The points are p	etcrney(s) and/or enterney(s) and en	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing of  (Firing Date)  (Fi	c of any United States discissed in the prior lead according to the prior lead according to the application and william W. Rand act telephone number of the application of the prior lead according to the accordi	United States applied by the disclose in became available  (State - parents)  (State - parents)  (State - parents)  to transact all bus  Earl T.  olph, Reg #2  ber  DA  statements made all ge that willful false of the United State and thereon.  Date	ication in the manner formation which is between the filing did pending standoned pending standoned iness in the Reichert, 8,986;  on information and a statements and the es Code and that
hereby with the solution of th	as all correspondence to be five dealer that all statements may declare that all statements may declare that all statements may declare that all statements may me of third inventor signature needs to be true; are point of third inventor signature needs to be true; are point of third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be true; are points and third inventor signature needs to be points and third inventor signature needs to be points and third inventor signature needs to be points and the points and the points are points and the points and the points are points are points and the points are points and the points are points are points and the points are points. The points are p	etcrney(s) and/or enterney(s) and en	d States Code, § 123 his application is not ed States Code, § 1 Code of Federal Flog imemational filing of  (Firing Date)  (Fi	c of any United States discissed in the prior lead according to the prior lead according to the application and william W. Rand act telephone number of the application of the prior lead according to the accordi	United States applied by the disclose in became available  (State - parents (State - parents)  Earl T.  olph, Reg #2  ber  DA  statements made loge that willful false of the United State and thereon.  Date	ication in the manner formation which is between the filing did pending standoned pending standoned iness in the Reichert, 8,986;  on information and a statements and the es Code and that

### DECLARATION FOR PATENT APPLICATION As a below named inventor, I hereby decla at: Ramasubbu Jeyanthi, John E. n Hamont, Robert H. Reid, F. Donald Robe. s, Charles E. McQueen, Jean A. etterstrom n Hamont, Phil Friden, My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Novel "Burst-Free" Sustained Release Poly (Lactide/Glycolide) the specification of , the specification of which Microspheres is attached hereto unless the following box is checked: as United States Application Number or PCT International Application $_{\rm X}$ was filed on $_{\rm 1}/24/96$ and was amended on \_\_\_\_\_ Number 08/590,973 I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Priority Claimed Prior Foreign Application(s) Yes No (Day/Month/Year Filed) (Country) (Number) ☐ Yes ☐ No (Day/Month/Year Filed) (Country) (Number) Yes No O (Day/Montt/Year Feed) (Number) (Country) L Thereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner grovided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is meterial to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filling date of the prior application and the national or PCT international filing date of this application. (Status - patented, pending, schandoned) (Application Number) (Frinc Date) (Status - patiented, pending abandoned) (Application Number) (Finc Date) Thereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Fragmand Trademark Office connected therewith: Earl T. Reichert, Reg #24,331; Werten F.W. Bellamy Reg #27,029; William W. Randolph, Reg #28,986; Maj Murray B. Baxter, Reg #33,646 at telephone number Address all telephone calls to Address all correspondence to INTELLECTUAL PROPERTY LAW DIVISION OFFICE OF THE JUDGE ADVOCATE GENERAL. 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jecpardize the validity of the application or any patent issued thereon. Full name of fourth inventor (given name, family name). Robert H. Reid State Reiner. Date Residence 48 Lake Side TV. C.V., Fuit Post Office Address Full name of secondoint inventor, if any (given name, family name) -Citizenship Residence. Post Office Address Additional inventors are being named on separately numbered sheets attached hereto. page 4 of 7

Docket Number (Optional)

Rot My r	lieve I am the original t	first and sole inventor (if only one n	ame is listed below) or an original, fi	irst and joint investor (# =
nam	nes are listed below) of	the subject matter which is claimed	and for which a patent is sought or	the invention entitled the specification of w
is at	ttached hereto unless t	the following box is checked:		
X	was filed on $1/24/9$	96 ss United States	Application Number or PCT Interna	tional Application
	Number 08/590	,973 and was amended	d on	(fi applicable)
l her	eby state that I have re	eviewed and understand the content	ts of the above identified specification	on including the claims of
	nded by any amendme			my more any the cicinis, a
lack	nowledge the duty to d	lisclose information which is materia	al to patentability as defined in Title :	37, Code of Federal
	ulations, § 1.56.			
invor I Deci	eby daim foreign priori	ty benefits under Title 35, United St	ates Code, § 119 of any foreign app	lication(s) for patent or
havir	nors certificate listed b	pelow and have also identified below hat of the application on which prior	v any toreign application for patent o ity is chaimed	r inventor's certificate
	Foreign Application(s)		ny E delinoc.	Priority Claim
1.	1 oreign Approation(s)	·		•
	(Number)	(County)	(Day/Mont/Year Fred)	Yes   No
				Yes [] No
A1149	(Number)	(County)	(Day/Mont/Year Filed)	□ V•• □ N•
	(Number)	(County)	(Day/Mont/Year Féed)	Yes [] No
į.				
the povice	e subject matter of each ded by the first paragra; rial to patentability as di	der Trile 35. United States Code. § not the daims of this application is replication of the Code. § of the 35. United States Code. § of the derivation of Federal File national or PCT international filing	not disclosed in the prior United State § 112, I acknowledge the duty to disc regulations, § 1.56 which became av	es application in the man dose information which is
the	e subject matter of each ded by the first paragra; rial to patentability as di	n of the claims of this application is r ph of Trile 35, United States Code, § etined in Trile 37, Code of Federal F	not disclosed in the prior United State 112, I acknowledge the duty to disc segulations, § 1.56 which became aving date of this application.	es application in the man dose information which is allable between the filing
the the	e subject matter of each ded by the first paragray rial to patentability as deprior application and the prior application and the prior application and the prior application and the prior application for the prior application and the prior application for the prior application for the prior application for the prior application and the prior application for the prior application application for the prior application application application for the prior application applicatio	n of the claims of this application is replication of the claims of this application is replication of the claim of the cl	not discosed in the prior United State § 112, I acknowledge the duty to discovered the discovered the application.	es application in the man dose information which is allable between the filing parented, pending scandon
the spice	e subject matter of each ded by the first paragray rial to patentability as deprior application and the abon Number)	n of the claims of this application is rept of Trile 35, United States Code, § efined in Trile 37, Code of Federal Fine national or PCT international filing (Firing Date)	not disclosed in the prior United State \$112, I acknowledge the duty to disclegulations, \$1.56 which became avg date of this application.  (State = page 1)	es application in the man tiose information which is allable between the filing patented, pending sciandon extented, pending sciandone
the price	e subject matter of each ded by the first paragragial to patentability as deprior application and the subject of the following that the following that are subject to the follow	nof the daims of this application is replication for the 35, United States Code, gettined in Title 37, Code of Federal Fine national or PCT international filling (First Date)	not disclosed in the prior United State § 112, I acknowledge the duty to disc legulations, § 1.56 which became av g date of this application.  (State = p	es application in the manifese information which is allable between the filing parented, pending abandons all business in the
	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application and the prior application and the prior application and the prior application for the following and Trademark Office (24,331; Werten durray B. Baxter as all telephone calls to	nof the daims of this application is replication of Trile 35, United States Code, gettined in Trile 37, Code of Federal Fine national or PCT international filling (Fing Date)  (Fing Date)  (Fing Date)  attorney(s) and/or agent(s) to prose connected therewith:  F.W. Bellamy, Reg #27,029, Reg #33,646	not discosed in the prior United State  112, I acknowledge the duty to disc  legulations, § 1.56 which became av  g date of this application.  (Satis - p  scute this application and to transact  Ear  9; William W. Randolph, R  at telephone number	es application in the manifese information which is allable between the filing parented pending scandon extented pending scandone all business in the 1 T. Reichert, eg #28,986;
	e subject matter of each ded by the first paragragial to patentability as deprior application and the subject of the following that the following that are subject to the follow	nof the daims of this application is replication of Trile 35, United States Code, gettined in Trile 37, Code of Federal File national or PCT international filling (Fing Date)  (Fing Date)  (Fing Date)  attorney(s) and/or agent(s) to prose connected therewith: F.W. Bellamy, Reg #27,029, Reg #33,646	cot discosed in the prior United State  112, I acknowledge the duty to disc  legulations, § 1.56 which became av  clate of this application.  (Satis - p  coute this application and to transact  Ear  ); William W. Randolph, R  at telephone number  LAW DIVISION	es application in the manificse information which is allable between the filing paramed, pending scandon exampled, pending scandone all business in the 1 T. Reichert, eg #28,986;
	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application and the prior application and the prior application and the prior application for the following and Trademark Office (24,331; Werten durray B. Baxter as all telephone calls to	nof the daims of this application is replication of Trile 35, United States Code, gettined in Trile 37, Code of Federal Fine national or PCT international filling (Fing Date)  (Fing Date)  (Fing Date)  attorney(s) and/or agent(s) to prose connected therewith:  F.W. Bellamy, Reg #27,029, Reg #33,646	not discosed in the prior United State  112, I acknowledge the duty to disc  Regulations, § 1.56 which became av  g date of this application.  (Sate - p  Cours - p	es application in the manificse information which is allable between the filing paramed, pending scandon exampled, pending scandone all business in the 1 T. Reichert, eg #28,986;
	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application and the prior application and the prior application and the prior application for the following and Trademark Office (24,331; Werten durray B. Baxter as all telephone calls to	of the daims of this application is replication of the daims of this application is replication of the 35. United States Code, gettined in Title 37. Code of Federal File national or PCT international filling (Fing Date)	not discosed in the prior United State  112, I acknowledge the duty to disc  Regulations, § 1.56 which became av  g date of this application.  (Sate - p  Course -	es application in the manicose information which is allable between the filing paramed, pending scandon scanned pending scandone all business in the 1 T. Reichert, eg #28,986;
the point of the p	e subject matter of each ded by the first paragrayinal to patentability as deprior application and the prior application and the prior Number)  ation Number)  by appoint the following and Trademark Office (24, 331; Werten sturray R. Baxter as all telephone calls to as all correspondence to	re of the claims of this application is rept of Trile 35. United States Code. Eather Code of Trile 37. Code of Federal File national or PCT international filing (First Date)	cot discosed in the prior United State  112, I scinowiedge the duty to disc  regulations, § 1.56 which became av  cate of this application.  (Satist - p  coute this application and to transact  Ear  ); William W. Randolph, R  at telephone number  LAW DIVISION  DVOCATE GENERAL, DA  ET, SUITE 700  1837	es application in the man close information which is allable between the filing patented pending abandon attented pending abandone all business in the 1 T. Reichert, eg #28,986;
the rovice of the rotation of	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application and the prior application and the prior application and the prior application for the following and Trademark Office (24,331; Werten standard R. Baxter as all telephone calls to as all correspondence to be declared that all statem re believed to be true; as the prior to be t	of the daims of this application is replication of the daims of this application is replication. The 35, United States Code, gettined in This 37, Code of Federal File national or PCT international filling (Fing Date)	not discosed in the prior United State  112, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  13, I acknowledge the duty to disc  14, I acknowledge the duty to disc  15, I acknowledge the duty to disc  16, I acknowledge that will  11, I acknowledge that will  12, I acknowledge that will  13, I acknowledge that will  14, I acknowledge that will  15, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowl	es application in the manifose information which is allable between the filing parented pending standon all business in the 1 T. Reichert, eg #28,986;  made on information and full false statements and its statements and i
the point of the p	e subject matter of each ded by the first paragray rial to patentability as deprior application and the prior application and the prior application and the aton Number)  aton Number)  by appoint the following that Trademark Office for a Baxter and the prior all the prior all the prior and the pr	riof the daims of this application is right of Trile 35. United States Code, gettined in Trile 37. Code of Federal File national or PCT international filling (Firing Date)	not discosed in the prior United State  112, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  13, I acknowledge the duty to disc  14, I acknowledge the duty to disc  15, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowledge that will  19, I acknowledge that will  10, I acknowledge that will  10, I acknowledge that will  11, I acknowledge that will  12, I acknowledge that will  13, I acknowledge that will  14, I acknowledge that will  15, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowledge that will  18, I acknowledge that will  19, I acknowledge that will  19, I acknowledge that will  10, I acknowledge that will  10, I acknowledge that will  11, I acknowledge that will  12, I acknowledge that will  13, I acknowledge that will  14, I acknowledge that will  15, I acknowledge that will  16, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowledge th	es application in the manifose information which is allable between the filing parented pending scandon all business in the 1 T. Reichert, eg #28,986;  made on information and full false statements and that
the povice of the property of	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application and the prior application and the prior application and the prior application number)  ation Number)  by appoint the following and Trademark Office (24, 331; Werten durray B. Baxter as all telephone calls to as all correspondence to be true; and are punishable by declare that all statemare believed to be true; and are punishable by tillful false statements militual false fal	reference of the daims of this application is reported in Trile 35. United States Code, gettined in Trile 37. Code of Federal Filter and in Trile 37. Code of Federal Filter and filter (Fire Date)	not discosed in the prior United State  112, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  13, I acknowledge the duty to disc  14, I acknowledge the duty to disc  15, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowledge that will  19, I acknowledge that will  10, I acknowledge that will  10, I acknowledge that will  11, I acknowledge that will  12, I acknowledge that will  13, I acknowledge that will  14, I acknowledge that will  15, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowledge that will  18, I acknowledge that will  19, I acknowledge that will  19, I acknowledge that will  10, I acknowledge that will  10, I acknowledge that will  11, I acknowledge that will  12, I acknowledge that will  13, I acknowledge that will  14, I acknowledge that will  15, I acknowledge that will  16, I acknowledge that will  16, I acknowledge that will  17, I acknowledge that will  18, I acknowledge th	es application in the manifose information which is allable between the filing parented pending scandon all business in the 1 T. Reichert, eg #28,986;  made on information and full false statements and that
the policy of th	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application number)  by appoint the following and Trademark Office (24, 331; Werten and Trademark Office (24, 331; Werten and telephone calls to as all correspondence to be all correspondence to be believed to be true; a made are punishable by applications of fifth inventions of fifth inventions of the prior and the prior applications of the prior and the prior applications of the prior application and the prior application a	reference of the daims of this application is reported for the 35. United States Code, gettined in Trile 37. Code of Federal Filter and in Trile 37. Code of Federal Filter (First Date)	cot discosed in the prior United States  112, I acknowledge the duty to discoveredge the duty to	made on Information and that set states and that
the povice of the population o	e subject matter of each ded by the first paragrayinal to patentability as deprive application and the prior application and the prior application and the prior humber)  atton Number)  by appoint the following and Trademark Office (24, 331; Werten stall telephone calls to as all correspondence to the prior application and are punishable by illful false statements minuted of fifth inventor signature.	re of the claims of this application is rept of Trile 35. United States Code. Entered in Trile 37. Code of Federal File and in Trile 37. Code of Federal File national or PCT international filing (Fing Date)	cot discissed in the prior United State  112, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  13, I acknowledge the duty to disc  14, I acknowledge the duty to disc  15, I acknowledge that will acknowledge that will ar Section 1001 of Tate 18 of the United to Date  15, Date  16, Date  17, Date  18, Date  10, Date  11, Date  12, Date  13, Date  14, Date  15, Date  16, Date  16, Date  17, Date  18, Date	made on Information and ted States Code and that
the povice of the population o	a subject matter of each ded by the first paragrayinal to patentability as deprivation and the prior application and the prior application and the prior humber)  atton Number)  by appoint the following and Trademark Office (24, 331; Werten statemark office as all telephone calls to as all correspondence to the believed to be true; and are punishable by allful false statements minuted of fifth inventor signaturince 2 BR	roof the claims of this application is rept of Trile 35. United States Code, gettined in Trile 37. Code of Federal File national or PCT international filling (Fang Date)  (Fing Date)  (Fi	cot discosed in the prior United States  112, I acknowledge the duty to discoveredge the duty to	made on Information and ted States Code and that
the povice of the property of	e subject matter of each ded by the first paragray as de prior application and the prior applica	riof the claims of this application is replication of the claims of this application is replication. The 35, United States Code, gettined in This 37, Code of Federal File national or PCT international filling (Fang Date)  (Fing Date)  (Fin	not discosed in the prior United State  112, I acknowledge the duty to disc  112, I acknowledge the duty to disc  12, I acknowledge the duty to disc  12, I acknowledge the duty to disc  13, I acknowledge the duty to disc  14, I acknowledge the duty to disc  15, I acknowledge that will all statements  16, I acknowledge that will ar Section 1001 of Tatle 18 of the Unit  17, I acknowledge that will acknowledge that will ar Section 1001 of Tatle 18 of the Unit  16, I acknowledge that will acknowledge that will ar Section 1001 of Tatle 18 of the Unit  17, I acknowledge that will ar Section 1001 of Tatle 18 of the Unit  18, I acknowledge that will ar Section 1001 of Tatle 18 of the Unit  19, I acknowledge that will ar Section 1001 of Tatle 18 of the Unit  10, I acknowledge that will are section 1001 of Tatle 18 of the Unit  10, I acknowledge that will are section 1001 of Tatle 18 of the Unit  10, I acknowledge that will are section 1001 of Tatle 18 of the Unit  10, I acknowledge that will are section 1001 of Tatle 18 of the Unit  11, I acknowledge that will are section 1001 of Tatle 18 of the Unit  12, I acknowledge that will are section 1001 of Tatle 18 of the Unit  13, I acknowledge that will are section 1001 of Tatle 18 of the Unit  14, I acknowledge that will are section 1001 of Tatle 18 of the Unit  15, I acknowledge that will are section 1001 of Tatle 18 of the Unit  16, I acknowledge that will are section 1001 of Tatle 18 of the Unit  16, I acknowledge that will are section 1001 of Tatle 18 of the Unit	made on Information and teld States Code and that
the povice of the population o	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application for the following and Trademark Office (24, 331; Werten durray R. Baxter as all telephone calls to as all correspondence to be true; and are punishable by declare that all statem are believed to be true; a made are punishable by difful false statements minuted and fifth inventor signaturations.	riof the daims of this application is replication of the daims of this application is replication of the 35. United States Code, getined in Trile 37. Code of Federal File national or PCT international filing (First Date)  (Fir	cot discosed in the prior United State  112, I acknowledge the duty to disc  regulations, § 1.56 which became av  clate of this application.  (Satist - p  coute this application and to transact  Ear  Far  William W. Randolph, R  at telephone number  LAW DIVISION  DVOCATE GENERAL, DA  ET, SUITE 700  1837  Edge are true and that all statements  re made with the knowledge that will  in Section 1001 of Tale 18 of the Unit  ication or any patent issued thereon.  Donald Roberts  Chizenship  Charles E. McQueen	made on Information and the dissess at the states and that and States Code and that
the provide and the provide an	e subject matter of each ded by the first paragray and to patentability as deprior application and the prior application for application and the prior application and the pri	riof the claims of this application is replication of the claims of this application is replication. The 35, United States Code, gettined in This 37, Code of Federal File national or PCT international filling (Fang Date)  (Fing Date)  (Fin	cot discosed in the prior United State  112, I acknowledge the duty to disc  Sequilations, § 1.56 which became av  Cate of this application.  (Satistical  (Satis	made on information and that States Code and that

As a below named inventor, I h Robert H. Reid, F. Dor	ereby declar latt Ramasubbu hald Roberts, Charles E	. McOueen, Jean A.	. Setterstrom
My residence, post office addre	ess and citizenship are as stated t	below next to my name.	4
I believe I am the original, first names are listed below) of the Novel Burst-Free		na is listed below) or an on	iginal, first and joint inventor (if plural ught on the invention entitled ), the specification of which
Microspheres		_	
is attached hereto unless the form $x$ was filed on $1/24/96$	<del>-</del>	pplication Number or PCT	International Apolication
Number 08/590,973			(if applicable).
amended by any amendment re	ved and understand the contents eferred to above.		
	se information which is material t	to patentability as defined i	in Title 37, Code of Federal
Regulations, § 1.56.	" I Tale DE Llaited Stat	- C £ 110 of any fora	tion continuition(s) for natent or
inventor's certificate listed below	enefits under Title 35, United Stati wand have also identified below a of the application on which priority	any foreign application for p	patent or inventor's certificate
Prior Foreign Application(s)			Priority Claimed
· · · · · · · · · · · · · · · · · · ·			Yes 🗌 No
(Number)	(Country)	(Day/Month/Year Fil	led) Yes [] No
(Number)	(County)	(Day/Month/Year Fix	ed)
(Number)	(Country)	(Day/Montt/Year Fix	
of the prior application and the n	ational or PCT international filing	date of this application.	came available between the filing date
(Application Number)	(Filing Date)		Status - patented, pending, scandoned)
(Application Number)	(Fling Date)		Status - patented, pending, abandoned)
Patent and Trademark Office cor Reg #27,029; William W	princy(s) and/or agent(s) to prosect injected therewith: Earl T. Review Randolph, Reg #28,986	eichert, Reg #24,33 5; Maj Murray B. Ba	31; Werten F.W. Bellamy axter, Reg #33,646
Address all telephone calls to _	INTELLECTUAL PROPERTY	at telephone number	r
Address all correspondence to _	OFFICE OF THE JUDGE AD		
_ _	901 NORTH STUART STREE		
_	ARLINGTON, VA 22203-1		
belief are believed to be true; and like so made are punishable by fir	ts made herein of my own knowled further that these statements were ne or imprisonment, or both, under jeopardize the validity of the applic	e made with the knowledge r Section 1001 of Title 18 of	e that willful false statements and the f the United States Code and that
Full name of sixth inventor	•		Charles M: ( Juen
	Charles E. McQueen	· D	)ate 10 May 86
<del></del>	thelwood Ter	c	Atizenship usa
Post Office Address	J MD 20835		
Full name of as any driet inventor	r, if any (given name, family name)	1	
Lou name o Secondour maerro	', if any (given name, raimy raimy		rate
Residence			itizenship
Post Office Address			
Additional inventors are being	g named on separately numbered	sheets attached hereto.	page 6 of 7

DECLARATIO" FOR PATENT APPLICATION

Docket Number (Optional)

# DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby decia nat: Ramasubbu Jeyanthi, John E.

Docket Number (Optional)

amont, Phil Friden.

Robert H. Reid, F. Donald Roberts, Charles E. McQueen, Jean A. Setterstrom by residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled \_ the specification of which is attached hereto unless the following box is checked: as United States Application Number or PCT International Application x was filed on 1/24/96 (if applicable). and was amended on \_\_\_\_\_ Number 08/590,973 I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Priority Claimed Prior Foreign Application(s) ☐ Yes ☐ No (Day/Montt/Year Fied) (Country) (Number) Yes No (Day/Mont/Year Filed) (Country) (Number) Yes No (Day/Month Year Food) (Number) (Country) IJ The reby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar 뼕 the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner govided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date the prior application and the national or PCT international filing date of this application. (Status - patiented, pending, sciandoned) (Fing Date) (Application Number) (Fing Date) (Status - patiented pending abandoned) (Application Number) thereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Facent and Trademark Office connected therewith; tari T. Reichers Reg #24,331; Werten F.W. Bellamy, Reg #27,029; William W. Randolph, Reg #28,986; Earl T. Reichert, Maj Murray B. Baxter, Reg #33,646 at telephone number Address all telephone calls to :Address all correspondence to INTELLECTUAL PROPERTY LAW DIVISION OFFICE OF THE JUDGE ADVOCATE GENERAL. 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Jean A. Setterstrom Full name of seventh inventor (given name, family name) Jean a. Setterstrom Date 9 Hay 1996 \* signature Flesidence \_ 407 Boston Ave Full name of pint inventor, if any (given name, family name) \_ \_ Date \_ inventor signature Citizenship Residence. Post Office Address . Additional inventors are being named on separately numbered sheets attached hereto. page 7 of 7